JPH0121909B2 - - Google Patents
Info
- Publication number
- JPH0121909B2 JPH0121909B2 JP56069246A JP6924681A JPH0121909B2 JP H0121909 B2 JPH0121909 B2 JP H0121909B2 JP 56069246 A JP56069246 A JP 56069246A JP 6924681 A JP6924681 A JP 6924681A JP H0121909 B2 JPH0121909 B2 JP H0121909B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cells
- amount
- peripheral blood
- blood mononuclear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000000034 method Methods 0.000 claims abstract description 52
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 48
- 239000000427 antigen Substances 0.000 claims abstract description 41
- 102000036639 antigens Human genes 0.000 claims abstract description 41
- 108091007433 antigens Proteins 0.000 claims abstract description 41
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims abstract description 31
- 201000011510 cancer Diseases 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 17
- 102000008857 Ferritin Human genes 0.000 claims description 117
- 108050000784 Ferritin Proteins 0.000 claims description 117
- 238000008416 Ferritin Methods 0.000 claims description 115
- 210000004027 cell Anatomy 0.000 claims description 104
- 210000004698 lymphocyte Anatomy 0.000 claims description 51
- 238000012360 testing method Methods 0.000 claims description 49
- 230000027455 binding Effects 0.000 claims description 25
- 210000000265 leukocyte Anatomy 0.000 claims description 16
- 230000009870 specific binding Effects 0.000 claims description 15
- 239000011886 peripheral blood Substances 0.000 claims description 13
- 210000005259 peripheral blood Anatomy 0.000 claims description 13
- 102000004641 Fetal Proteins Human genes 0.000 claims description 7
- 108010003471 Fetal Proteins Proteins 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 6
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 230000002285 radioactive effect Effects 0.000 claims description 6
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 5
- 210000001161 mammalian embryo Anatomy 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims 4
- 210000005087 mononuclear cell Anatomy 0.000 abstract description 8
- 238000003018 immunoassay Methods 0.000 abstract description 6
- 238000009007 Diagnostic Kit Methods 0.000 abstract 1
- 230000009137 competitive binding Effects 0.000 abstract 1
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 238000003908 quality control method Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 22
- 239000011521 glass Substances 0.000 description 15
- 206010006187 Breast cancer Diseases 0.000 description 10
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 230000003211 malignant effect Effects 0.000 description 10
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000017604 Hodgkin disease Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000012113 quantitative test Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000000439 tumor marker Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 206010051814 Eschar Diseases 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 208000001287 Galactorrhea Diseases 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000028958 Hyperferritinemia Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 238000003450 affinity purification method Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 125000005442 diisocyanate group Chemical group 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 231100000333 eschar Toxicity 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 208000018212 fibroblastic neoplasm Diseases 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000004802 monitoring treatment efficacy Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000002281 placental hormone Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000012834 spinner culture method Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57476—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofetal proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
æ¬çºæã¯åæ žè¡çã®è¡šé¢ã«ãªã³ã³ãã€ãŒã¿ã«ã¢
ã³ãã€ãžãšã³ãååšãããã©ããã決å®ããæ¹æ³
ããã³è£ 眮ãç¹ã«è©Šè¬ã®ç掻åãããšãã¯ããæ
段ãšè©Šéšã®ä¿¡é Œæ§ãäžããããã«ç¹æ®ãªéœæ§å¯Ÿç §
ã䜿çšããæåâæäœã¿ã€ãã®å ç«æž¬å®æ¹æ³ã®æ¹
è¯ã«é¢ãããã®ã§ããã ç±³åœç¹èš±ç¬¬4116776å·ã«ã¯äººéã®èç€ãã«ã¢ã³
ïŒhCGïŒããªã³ãçäžã«ååšãããã©ããã決å®
ããæ¹æ³ãé瀺ãããŠããããã®æ¹æ³ã¯ã¬ã³ã®æ€
æ»ãšããŠã®ç·æ§ããã³åŠåš ããŠããªã女æ§ã®hCG
ã®æ€åºæ¹æ³ãæ¹è¯ãããã®ã§ããããã®ç¹èš±ã®çº
æè ã¯è¡æž äžã®hCGã®æç¡ãæ€æ»ããããã®åŸæ¥
ã®ã©ãžãªã€ã ãã¢ãã»ã€ãã¹ãã«èšåãã宿䞻ã®
ãªã³ã现èãæªæ§ã®è «ç现èã«ãã€ãŠåæ²ããã
hCGãéããŠãã®hCGãšçµåããããšãçºèŠãã
ãšèšã€ãŠããããããŠãã®ç¹èš±ã®è©Šéšã¯åŸæ¥ã®è¡
æž è©Šéšã«æ¯ã¹ãŠæ床ãé«ãããšãç¹åŸŽãšãããã®
ã§ãããšè¿°ã¹ãŠããããã®ç¹èš±ã®æ¹æ³ã«ãããŠ
ã¯ãåèšãªã³ãçã«çµåããhCGååããã·ã¢ãª
ã³é žæ®æ»ãé€å»ããåŸããã®ãªã³ãçãhCGã®ãµ
ããŠãããã«ç¹ç°çãªæšèããæè¡æž ã«ãããã
平衡ã«éããåŸã«ãã®æšèãäŸãã°è¢å ãæŸå°æŽ»
æ§ãã®éã枬å®ããããšã«ãã€ãŠhCGã®æ¿åºŠã枬
å®ãããæ¢ç¥ã®å¥åº·äººã®è¡æ¶²ãåãæšèã«ã€ãã
ããéžæãããéç¹ç°çæè¡æž çã®é°æ§å¯Ÿç §ãã
ãã®æ¹æ³ã§ã¯éåžžçšããããã ç±³åœç¹èš±ç¬¬3988115å·ã«ã¯ãããªã¬ã³ãã«çµå
ããããšã®ã§ãããªã³ãçã®éã決å®ããè©Šéšã
é瀺ãããŠããããã®è©Šéšã¯ãã®ãªã¬ã³ãã«ç¹ç°
çãªã¬ã»ãã¿ãŒãæãããªã³ãçãšçžäºã«äœçš
ãããã®ç¹ç°çãªã¬ã»ãã¿ãŒãæãããªã³ãçã®
ã¿ã®å¢çãåºæ¿ãããªã¬ã³ãã«åºã¥ããã®ã§ã
ãããã®ãªã¬ã³ãã«ç¹ç°çãªã¬ã»ãã¿ãŒãæãã
ãªã³ãçã®éãæ€åºããã®ã«æšèãããªã¬ã³ãã
䜿çšãããããã®è©Šéšã®é·æã¯è¡æµäžã«å€éã®æ
äœãååšããåã§ã䜿çšã§ããããšã§ãããšäžèš
ç¹èš±ã«ã¯èšèŒãããŠãããã²ã«ããŒãºã«åžåãã
ãæäœçã®æå®ã®ãªã¬ã³ãçµå掻æ§ãæããç²å
ãããã¯æ£åžžäººã®è¡æ¶²ãå¯Ÿç §ãšããŠäœ¿çšãããã ããã³ãïŒRockoffïŒçã®ãSensitive and
Covenient Quantitation of Antibody Binding
to Cellular Antigens Using Glutaraldehyde
Preserved CellsãïŒJournal of Immunological
Methodsã26ã369ã1979ïŒã«ã¯ã°ã«ã¿ã«ã¢ã«ã
ããåºå®ããæšç现èã䜿çšããŠã¬ã³ã«ç¹ç°çãª
æäœãæ€åºããå®éããæ¹æ³ãèšèŒãããŠããã
å¯Ÿç §ã¯æ£åžžè¡æž ãšæ¶²äœå¹å°ã§ããã ããã·ãžãŠãã€ïŒTomasiãJr.ïŒã®
ãStructure and Functions of Alphaâfetopâ
roteinãïŒAnn Rev.Med.ã1977ã28ïŒ453ïŒã«
ã¯ãæè¬ãã¬ã³ã«ãããæã家æãã®æ«æ¢¢åæ žè¡
çã®è¡šé¢ã«ã¯ã¢ã«ãã¢èå èçœè³ªïŒAFPããªã³
ã³ãã€ãŒã¿ã«ïŒoncofetalïŒã¢ã³ãã€ãžãšã³ã®äž
çš®ïŒã®çºççãé«ãããšãèšèŒãããŠãããæ¬çº
æè ã®åŸãæ å ±ã«ããã°ãããã·ãžãŠãã€ã¯è¢å
å ç«æž¬å®æ³ã«ãã€ãŠãæAFPæäœã®åç¹ç°æ§ã
ã©ã°ã¡ã³ããååŠçã«ãã«ãªã¬ã»ã€ã³ã«çµåã
ãããããæ£è ã®ãªã³ãçãšãšãã«å¹é€ããåŸã
é¡åŸ®é¡äžã§éœæ§çŽ°èãèšæ°ããã ããŒãã³ïŒNaughtonïŒçã®ãLocalization of
the β Chain of Human Chorionic
Gonadotropin on Human Tumor Cells and
Placental CellsãïŒCancer Researchã35ã1887
ïŒ1975ïŒïŒã«ã¯é µçŽ æšèããhCGæäœã䜿çšããŠäºº
éã®è «ç现èã®è¡šé¢äžã«hCGãäœçœ®ãããããšã
èšèŒãããŠããã ããïŒã€ã®ãªã³ã³ãã€ãŒã¿ã«èçœã§ããããšãª
ãã³ã¯æœå¢è «çããŒã«ãŒã§ããããšãç¥ãããŠã
ããããŒã«ã¹ïŒMarcusïŒçã®ãSerum Ferritin
Levels in Patients with Breast Cancerã
ïŒClin.Res.ã23ã447ïŒ1975ïŒïŒã«ã¯äºéæäœã©ãž
ãªã€ã ãã¢ãã»ã€æ³ã«ãã€ãŠè¡æž ããšãªãã³ã枬
å®ããããšãèšèŒãããŠãããããã«å¯ŸããŠã¢ã
ãïŒMorozïŒçã®ããæè¿ã®è«æã«ããã°ãã
ãç¹ç°çãªæªæ§è «çããŒã«ãŒã¯ããšãªãã³ãæ ã€
ããªã³ãçã®ååšã§ãããïŒãLymphocytes
Bearing Surface Ferritin in Patient with
Hodgkinâ²s Disease and Breast CancerãâThe
New England Journal of Medicineã
correspondenceã276ãNo.20ã1172ïŒ1977ïŒãã
ã³ãFerritinâBearing Lymphocytes and â
cell Levels in Peripheral Blood of Patients
with Breast CancerãâCancer Immunol.
Immunother.ãïŒã101ïŒ1977ïŒåç §ïŒã¢ããçã¯
ããšãªãã³ãæ ã€ã现èã決å®ããã®ã«çŽ°èå·å®³
ãã¹ããçšãããããªãã¡æ£è ã®ãªã³ãçã«æäœ
ãå ããåŸãè£äœãå ããŠè¡šé¢ã«æäœãæããªã
现èãç Žå£ããæ»ãã 现èã«ãã€ãŠã¯æé€ãããª
ããããªã¿ã€ãã®æšæºçãªè²çŽ ãçšããŠæ»ãã 现
èã®æ°ã決å®ããã æ¬çºæã¯æ«æ¢¢è¡æ¶²ãªã³ãçäžã®å°ãªããšãïŒçš®
ã®ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãæ€åºããã
ãšã®ã§ããè¡æ¶²ãã¹ãæ¹æ³ãæäŸããããšãç®ç
ãšãããã®ã§ããã ããã«æ¬çºæã¯æ«æ¢¢è¡æ¶²ãªã³ãçäžã®ããšãªã
ã³ãæ€åºããããã®è¡æ¶²ãã¹ãæ¹æ³ãæäŸããã
ãšãç®çãšãããã®ã§ããã ããã«æ¬çºæã¯å°ãªããšãïŒã€ã®ããšãªãã³ç
ã®ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãæ ãæ«æ¢¢è¡
液ãªã³ãçã®éšåæ¯éå£ãå®éããæ¹æ³ãæäŸã
ãããšãç®çãšãããã®ã§ããã ããã«æ¬çºæã¯æ«æ¢¢è¡æ¶²ãªã³ãçäžã®ãªã³ã³ã
ã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã®æç¡ãå®éçä¹è³åå®
éçæ¹æ³ã§æ±ºå®ããããšãã§ãããã€ãã®ãã¹ã
ã®æå¹æ§ã確èªããã®ã«ãªã³ãçã«ä»çãããã
ãããªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãããªãéœ
æ§å¯Ÿç §ã䜿çšããããã«ããæšèåŒã®æ¹è¯ããã
å ç«æž¬å®æ¹æ³ãæäŸããããšãç®çãšãããã®ã§
ããã ããã«æ¬çºæã¯å°ãªããšãããçš®ã®ã¬ã³ãæ©æ
çºèŠä¹è³äºç¥ããããšã®ã§ããæšèåŒã®å ç«æž¬å®
æ¹æ³ãæäŸããããšãç®çãšãããã®ã§ããã ãŸãæ¬çºæã¯äžèšã®ãããªæ¹æ³ãå®æœãããã
ã®è£ 眮ããªãã¡è©ŠéšããããæäŸããããšãç®ç
ãšãããã®ã§ããã æ¬çºæè ã¯æ«æ¢¢è¡æ¶²åæ žçŽ°èïŒperipheral
blood mononuclear cellïŒãäŸãã°ãªã³ãçäžã®
å°ãªããšãïŒã€ã®ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãš
ã³ã次ã®ãããªæ¹æ³ã«ãã€ãŠåå®éçä¹è³å®éç
ã«æ€åºã§ããããšãçºèŠããã (A) æ£è ã®æ«æ¢¢è¡æ¶²åæ žçŽ°èã®äžå®éããã®ãªã³
ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã«å¯Ÿããæšèãã
æäœãšæ··åããåã现èãµã³ãã«ã®æ¬¡ã®äžå®é
ããè©°æççµåé»å®³éã®ç²Ÿè£œããããã®ãªã³ã³
ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãå ããæšèããæ
äœãšæ··åããã (B) 次ã«ãæ¢ç¥ã®æåâéœæ§ã®æ«æ¢¢è¡æ¶²åæ žã¿ã€
ãã®çŽ°èãåèšæ£è ã®çŽ°èãµã³ãã«ã®æ¿ãã«äœ¿
çšããŠã(A)ãšåãæäœãããã次ã«ä»¥äžã«è©³è¿°
ãããããªèšç®ãè¡ãªãã å®éãè¡ãªãå Žåã«ã¯ãïŒçªç®ã®è©Šè¬ãããªã
ã¡ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã«åºå®ããã
æäœãåèšæšèããæäœããã³ç²Ÿè£œããæåãšãš
ãã«äœ¿çšããŠäžé£ã®æšæºæ²ç·ãäœæããã æ¬çºæã®äžå®æœäŸã«ãããŠã¯åèšãªã³ã³ãã€ãŒ
ã¿ã«ã¢ã³ãã€ãžãšã³ã¯ããããšãªãã³ã§ãããæ
äœã¯ãã¡ããæããããšãªãã³ã§ãããæŸå°æŽ»æ§
ãšãŠçŽ ãäŸãã°I125ã§æšèããã®ãæãŸããã æ¬çºæã¯ããã«æ¬çºæã®æ¹æ³ã«äœ¿çšãããè©Šè¬
ãå¥ã ã«å容ããè©Šè¬ãããããæäŸãããã®ã§
ããã 以äžæ¬çºæãæŽã«è©³çŽ°ã«èª¬æããã éå»æ°å¹Žã«äºã€ãŠãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãž
ãšã³ãæ€åºããå®éããããšããçååŠçãªç 究
ãå€ããªãããããã«ãªã€ãŠããããªã³ã³ãã€ãŒ
ã¿ã«ã¢ã³ãã€ãžãšã³ã¯éåžžã¯èå å ãããã¯ãæ£
åžžãªåŠå©Šå ã«hCGãååšããããã«ããéæªæ§ã®
ççåŠçæ¡ä»¶ã«ããæ人å ã«ã®ã¿å€éã«ååšã
ããããããªããã¬ã³ã«ããã€ãŠããããããã¯
ã¬ã³ã®çŽ å ãæããæ人ã«ããªã³ã³ãã€ãŒã¿ã«ã¢
ã³ãã€ãžãšã³ãååšããããšã次第ã«æããã«ãª
ã€ãŠæ¥ããããã§åé¡ãšãªãã®ã¯äžèšä»¥å€ã®çç
åŠçæ¡ä»¶äžã«ããæ人ã«ãäžè¿°ã®ããã«ãªã³ã³ã
ã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãååšããããšã§ããã
äŸãã°æ¶å管ã®ççæ§çŸç ã«ããã€ãŠããåŠåš ã
ãŠããªã女æ§ã®è¡æž äžã«ã¯hCGãååšããããæ¥
æ§èçãæ ¢æ§èèç害çã®æ£è ã®è¡æž äžã«ã¯ã¢ã«
ãã¢èå èçœè³ªãååšãããæè¿ã®ç 究ã«ãã€ãŠ
è¡æž ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãšæ«æ¢¢è¡æ¶²
åæ žçŽ°èã«çµåãããªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãž
ãšã³ã®åºå¥ãã€ãããã«ãªã€ãããšãããè«æã«
èšèŒãããŠããããã®è«æã«ããã°ãæªæ§ã®ç¶æ
ã«ãããããããã¯ãã®çŽ å ãæããç¶æ ã«ãã
ãšè¡æž äžã«ã§ã¯ãªãæ«æ¢¢è¡æ¶²åæ žçŽ°èã®è¡šé¢ã«å€
éã®ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãçºèŠãã
ããããã«ããã®è«æã¯ããªã³ã³ãã€ãŒã¿ã«ã¢ã³
ãã€ãžãšã³ãæ ãæ«æ¢¢è¡æ¶²åæ žçŽ°èã®éšåæ¯éå£
ã¯ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã®è¡æž ã¬ãã«
ãšã¯ç¡é¢ä¿ã§ãããæªæ§ã®çŽ å ã®ååšã«é¢ä¿ãã
ããšã匷ã䞻匵ããŠããã å€ãã®ç 究è ã人ã®æ£åžžãåŠããšãããšãªãã³
ã®é¢ä¿ã«æ³šç®ããŠãããããšãªãã³ã¯ååéçŽ
450000ã®éã貯èµããèçœã§ãããããšãªãã³ã¯
å®éã«ã¯è€æ°ã®ãµããŠããããããªã€ãŠãããã
ãªãã¡ååéçŽ18000ã®è€æ°ã®ã€ãœããšãªãã³ã
éå ±æçµåã«ãã€ãŠäºãã«çµåãããã®ã§ããã
å°ãªããšããã®ãã¡ã®å¹Ÿã€ãã®ã€ãœããšãªãã³ã
äºãã«åé¢ããããšã¯çé»ç¹ãå©çšããã°å¯èœã§
ãããçé»ç¹ãçŽ4.3ã5.0ã§ããã€ãœããšãªãã³
ã¯ç¹ã«é¢çœããã§ãããã¢ã«ããŒãïŒAlpertïŒ
çã®ãCarcinoâFoetal Human Liver
FerritinsãïŒNatureã242ã194ïŒïŒæ16æ¥ã
1973ïŒïŒãåç §ããããã αâïŒââã°ãããªã³ã¯èå ã®èèå ã«äž»ã«
çºèŠãããé žæ§ã€ãœããšãªãã³ã§ãããïŒçš®ã®ãª
ã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã§ããããèèè «
çãå¥åœ¢è «çã®çš®ã ã®æªæ§çŸç ãæããæ人å ã«
ãçºèŠããããå ç«åŠçã«ã¯ãæ£åžžãªããããšãª
ãã³ãããŸã åºå¥ãããŠããªãã€ãœããšãªãã³ã
å€ããããããªãããå ç«åŠçãªæäœç£çææ³ã
䜿çšããã°äžèšÎ±âïŒââã°ãããªã³ã5.1ã
5.6ã®çé»ç¹ãæããã€ãœããšãªãã³çã®ç¹å®ã®
ã€ãœããšãªãã³ã«å¯Ÿããæäœã¯ç£çããããšãã§
ãããšèããããã äžè¿°ã®ãããªåœç¶èµ·ããççåŠççŸè±¡ãããªã
ã¡ãããªãåºãæ¿åºŠç¯å²ã«äºã€ãŠæ£åžžã®è¡æž äžã«
ããšãªãã³ãååšããããçŸåšã®ãšããç°ãªãã€
ãœããšãªãã³ãå ç«åŠçã«åºå¥ããããšãã§ã
ããããã«éæªæ§ã®è²§è¡ã®ãããªéæªæ§ã®çŸç ç¶
æ ã«ãããšè¡æž ããšãªãã³ã¬ãã«ãäžæããããš
ãèãåããããšè¡æž ããšãªãã³ã¬ãã«ã蚺æã®
åºæºãšããããšã¯å°é£ã§ãããããç 究ã§æªæ§ã®
çŸç ã«ããã€ãŠããæ£è ããã¹ããããšãããã®
çŽ70ïŒ ã®è¡æž ããšãªãã³ã¬ãã«ãäžæããŠããã
ããã«ãåæã®ä¹³ããæ£è ã«ãããŠã¯è¡æž ããšãª
ãã³ã¬ãã«ã¯æ£åžžãªè¡æž ã®ããšãªãã³ã¬ãã«ãšãª
ãŒããŒã©ããããŠããããåçºæ§ãããã¯è»¢ç§»æ§
ã®ä¹³ããã«ããã€ãŠãã女æ§ã¯è¡æž ããšãªãã³ã¬
ãã«ã極ããŠé«ããšããå ±åããããã€ã³ã
ïŒJacobsïŒçã®ãSerum Ferritin Concentration
in  arly Breast CancerãïŒBr.J.Cancerã34
(3)ã286ïŒ1976ïŒïŒããSerum Ferritin
Concentration in Untreated Hodgkinâ²s
DiseaseãïŒåæž34(3)ã162ïŒ1976ïŒããµãŒã·ãã³
ïŒSarcinoneïŒçã®ãIncreased Ferritin
Synthesis and Release by Hodgkinâ²s Disease
in Peripheral Blood LymphocytesãïŒInt.J.
Cancerã20ã339ïŒ1977ïŒïŒããã³æ°æŽ¥çã®
ãRadioimmunoassay of Serum Ferritin in
Patients with MalignancyãïŒAnn.N.Y.Acad.
Sciã259ã450ïŒ1975ïŒïŒãåç §ããããã ã¢ããçã®ç 究ã®äžéšãåè¿°ããããã¢ããç
ã¯ããã«ãããšãªãã³èçœæåãããžãã³æ°ãªã³
ãæ§çµç¹è «ã«ãããŠïŒŽãªã³ãçã®é®æç©è³ªãšããŠ
äœçšããããã«ãã€ãŠãã®ãããªçŽ°èããããžèµ€
è¡çãšèªçºçã«ããŒããã圢æããã®ãæããã
ãšãçºèŠãããã¢ããçã®ãFerritin on the
Surface of Lymphocytes in Hodgkinâ²s
Disease Patientsâïœ Possible Blocking
Substance Removed by LevamisoleãïŒClin.
Exp.Immunol.ã29ã30ïŒ1977ïŒïŒãåç §ããã
ããããã«ãã€ãŠä¹³ããã®åŸŽåãšããŠã®ããšãªã
ã³ãæ ããªã³ãçãåè¿°ã®çŽ°èå·å®³ãã¹ãã«ãã€
ãŠå®éããããšããç 究ãå°ãããã®ããç¥ããª
ãããã®çŽ°èå·å®³ãã¹ãã®èããæ¬ ç¹ã®ïŒã€ã¯æ£
è ã®çŽ°èã«äœ¿çšãããåè©Šè¬ã®å¹æãå¥ã ã«è©äŸ¡
ããªããã°ãªããªããšããããšã§ããã æ¬çºæã®ããšãªãã³ãæ ããªã³ãçã®æ€åºå®é
æ¹æ³ã¯è¿ éã§ãã€äŸµå ¥æ§ããªããæ¬çºæã®ãã¹ã
æ¹æ³ã¯ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã®æ€åºã«
å®éšçã«äœ¿çšã§ããã ãã§ãªããä¹³ããçã®ã¬ã³
ã®çºèŠããã³æ²»çå¹æãè©äŸ¡ããã®ã«äœ¿çšããã
ãšãã§ããã 次ã«æ¬çºæã«äœ¿çšãããè©Šè¬ã«ã€ããŠèª¬æã
ãã (1) æšèããæããããšãªãã³æäœ ä»¥äžã«è¿°ã¹ãå®éšã«ãããŠäœ¿çšãããããšãª
ãã³æäœã¯åç¹ç°çããããšãªãã³æäœã§ã
ããããç¹ç°æ§ã®åŒ·ãæäœãããªãã¡ã€ãœããš
ãªãã³ç¹ç°çæäœãã以äžã«è¿°ã¹ãæšèããã
ãããšãªãã³æäœã®èª¿è£œæ¹æ³ã«ãããŠæ£åžžãªã
ãããšãªãã³ã®æ¿ãã«å°ãªããšãïŒçš®ã®ã€ãœã
ãšãªãã³ããªãã¡çé»çã«æ±ºå®ãããç¯å²ã®ã€
ãœããšãªãã³ã§çœ®æããããšã«ãã€ãŠèª¿è£œãã
ããšãã§ããã æšæºçãªå ç«åŠçãªæ¹æ³ãçšããŠã©ããããš
ããããšãªãã³ã§å ç«ããã次ã®ãããªèŠªåæ§
粟補æ¹æ³ã«ãã€ãŠåç¹ç°çæäœãç£çããããš
ãã§ãããç䟡ã®æ¹æ³ã¯åœæ¥è ã«ã¯å®¹æã«åã
ãã§ãããã ç²åãµã€ãº200ã400ã¡ãã·ãŠã®ã¢ãªã«ã¢ãã³
ã®å¶åŸ¡åïŒ1350â«ïŒã¬ã©ã¹ãã°ã«ã¿ã«ã¢ã«ãã
ãïŒã¬ã©ã¹ïŒïœåœããïŒmlïŒã§æŽ»æ§åãããã
ã®ã¬ã©ã¹ãæŽã€ãŠæªåå¿ã®ã°ã«ã¿ã«ã¢ã«ããã
ãé€å»ããåŸãã¬ã©ã¹ïŒïœåœããïŒmgã®ããã
ãšãªãã³ããã®æŽ»æ§åããã¬ã©ã¹ãšå®€æž©ã§çŽïŒ
æééãã«æ··åããã次ã«1Mã®å¡©åãããªãŠ
ã ãš0.1Mã®ã°ãªã·ã³ã§ç¶ããŠæŽããããã«
0.1Mã®ãªã³é žå¡©ç·©è¡æ¶²ã§ïŒãïŒåæŽãããã®
ã¢ãªã«ã¢ãã³ã¬ã©ã¹ã¯å ¬ç¥ã®æ¹æ³ã«ãã€ãŠå®¹æ
ã«èª¿è£œããããšãã§ãããäŸãã°ãWeetallã
Scienceã166ã615ïŒ1969ïŒããåç §ããããã 次ã«ãã®ããšãªãã³ã®çµåããã¬ã©ã¹ããã®
ã¬ã©ã¹ïŒïœåœããçŽïŒmlã®ããšãªãã³æè¡æž ãš
éãã«æ··åããã22âã§äžæ©å¹é€ããåŸ0.1M
ã®çé žãããªãŠã ã0.15Mã®å¡©åãããªãŠã
ïŒPH8.0ïŒã0.1Mã®é ¢é žãããªãŠã ããã³0.15M
ã®å¡©åãããªãŠã ïŒPH5.0ïŒã§ç¶ããŠæŽããã
ãã«1Mã®å¡©é žã§PH4.4ã«èª¿ç¯ããèžçæ°Žã§ïŒåºŠ
æŽããPH2.2ã«èª¿ç¯ããèžçæ°Žã§åç¹ç°çæäœ
ã溶åºãããããã®ã¹ã©ãªãŒã0.3Mã®ãªã³é ž
ãããªãŠã å ã«éãããã®æ¶²ãéå€éã«
ãã€ãŠæ¿çž®ãããæäœã¯0.02ïŒ ã®ã¢ãžåç©ãå«
ã0.1Mãªã³é žãããªãŠã 溶液å ã«è²¯èµããã
ãšãã§ããããã®æäœã¯æŸå°æŽ»æ§æšèãé µçŽ æš
èãè¢å æšèçåŸæ¥ã®ã©ã®ãããªæšèãšãçµå
ãããããšãã§ããããããã§ã¯ãã®åç¹ç°ç
ããããšãªãã³æäœã¯NaI125ã«ãã€ãŠæŸå°æŽ»æ§
æšèããã (2) ããšãªãã³éœæ§åæ žçŽ°è ãã®è©Šè¬ã¯äžèš(1)ã®è©Šè¬ã®å®å®æ§ãã¢ãã¿ãŒ
ããæ¬çºæã®æ¹æ³ã®æå¹æ§ã確èªããããã«éœ
æ§ã®å®æ§å¯Ÿç §ãšããŠäœ¿çšãããã ãã®è©Šè¬ã調補ããã®ã«äœ¿çšãããåæ žçŽ°è
ãšããŠã¯ãèªç¶ã®ãããªã³ãçã§ã¯èµ·ããã¡ãª
ããšãªãã³ã¬ãã«ã®å€åãé¿ããããã«å¹é€å¢
æ®ãããªã³ãçã䜿çšããã®ãæ®éã§ãããã
ãã§ã¯ãæ¥æ§ãªã³ãæ¯çŽ°èæ§çœè¡ç 现è
ïŒCCLâ119ãATCCïŒã䜿çšããããããºã
ãªã³ãçïŒCCLâ86ãŸãã¯CCLâ126ã©ã€ã³ïŒ
çã®ä»ã®å¹é€ããããªã³ãçã䜿çšããããšã
ã§ãããããŸãé©åãªç¯©åããã§ããã°æ£åžžãª
å®éšææã®æ«æ¢¢è¡æ¶²ãªã³ãçã§ã䜿çšããããš
ãã§ããããã®ãããªåæ žçŽ°èã¯ããªãã¡æ«æ¢¢
è¡æ¶²åæ žã¿ã€ãã®çŽ°èã§ããããã®ãããªçŽ°è
ã¯å€©ç¶ã®æ«æ¢¢è¡æ¶²åæ žçŽ°èãšäŒŒãè¡šé¢èç¹æ§ã
瀺ãããããã°ã倩ç¶ã®æ«æ¢¢è¡æ¶²åæ žçŽ°èã§ã
ãå¿ èŠã¯ãªãã ãã®å®éšã§ã¯ããã®éœæ§å®æ§å¯Ÿç §è©Šè¬çŽ°èã¯
10ïŒ ã®çã®èå ã®è¡æž ïŒFCSãGrand Island
Biological Co.ïŒããŠãŒãšãŒã¯å·ã°ã©ã³ãã¢ã€
ã©ã³ãïŒè£œïŒã§è£è¶³ããRPMIâ1640å¹é€åº
ïŒåäžïŒå ã§å¢æ®ããæ¥æ§ãªã³ãæ¯çŽ°èæ§çœè¡
ç 现èïŒCCLâ119ïŒã䜿çšããŠèª¿è£œãããã
ã®çŽ°èã¯æ¹æå¹é€æ³ã䜿çšããé£ç¶å¹é€ã«ãã€
ãŠå¢æ®ãããããšãã§ãã倧éçç£ã«é©ããŠã
ãããã®CCLâ119ã200ã300xïœ15åéé å¿
æ²æŸ±ãããŠæ¡éãããªã³é žç·©è¡é£å¡©æ°ŽïŒPBSã
0.01Mãªã³é žå¡©ã0.15Må¡©åãããªãŠã ãPH
7.4ïŒã§ïŒåºŠæŽã€ãããã®çŽ°èãïŒãïŒÃ107
åïŒmlãšãªãããã«PBSå ã§åæ§æãããå
åãªéã®ã°ã«ã¿ã«ã¢ã«ãããã®25ïŒ ïŒïœïŒïœïŒ
溶液ãå ããŠæçµçãªã°ã«ã¿ã«ã¢ã«ãããæ¿åºŠ
ãçŽïŒïŒ ãšãªãããã«ããããã®æ¿åºŠããé«ã
å¯åºŠã§æŽ»æ§åãããšåºç¯å²ã«äºã现èåéãèµ·
ããããã®çŽ°èã22âã§30åéé£ç¶çã«ããã
ãªããå¹é€ããåŸãé å¿æ²æŸ±ã«ãã€ãŠæ¡éããŠ
æŽã€ãã粟補ããããããšãªãã³ïŒã«ãªããªã«
ãã¢å·ãµã³ã«ãŒã¹ãªãã¹ãã®JBL Chemical
Company補ïŒãPBSã§åžéãã200ã300ÎŒïœïŒ
mlã®æ¿åºŠãšãããã®çŽ°èãã¬ããã«å åå ããŠ
现èæ¿åºŠãïŒãïŒÃ107åïŒmlãšãªãããã«ã
ãã ãã®çŽ°è22âã§30åéããããªããå¹é€ãã
ããã«16ã18æéïŒâã§å¹é€ããããã®çŽ°èã
åè¿°ã®ããã«ããŠæŽããïŒïŒ ã®çã®è¡æž ã¢ã«ã
ãã³ïŒBSAïŒãš0.2ïŒ ã®ã¢ãžåãããªãŠã ãå«
ãPBSå ã«æžæ¿ããããèªå°ããã现èã®æ
åã®éå£ããå¹³åååçã¯40ã50ïŒ ã§ãã€ãã
ãã®çŽ°èãïŒâã§ä¿åãã40æ¥éã«I125ã§æšè
ããããããšãªãã³æäœã®ç¹ç°ççµåã«ãã€ãŠ
è©äŸ¡ãããšãã掻æ§ã®æžå°ã¯10ïŒ ã®ã¿ã§ãã€
ãã ã©ãããã®æããããšãªãã³è¡æž ãšããã«ãª
ã¬ã»ã€ã³ã«çµåãããå±±çŸã®æã©ãããè¡æž ã
䜿çšããŠéæ¥å ç«è¢å æ³ã«ãã€ãŠãã®çŽ°èãè©
䟡ãããšãã43ïŒ ã®çŽ°èãè¢å ã瀺ããããã
ã«å¯ŸããŠãããšãªãã³ã«çµåãããŠããªã
CCLâ119ããªãã¡çã®è¡æž ã¢ã«ããã³ã«çµå
ãããCCLâ119ã¯è¢å ã瀺ããªãã€ãããã®
éœæ§å®æ§å¯Ÿç §çŽ°èã¯æ£åžžãªã©ãããè¡æž ãšãšã
ã«å¹é€ãããšãã«ã¯è¢å ã瀺ããªãã€ãããŸã
ãã®çŽ°èäžã®ããšãªãã³ã®éã¯çŽ25ã40nïœïŒ
2.5Ã105åã§ãã€ãã (3) 粟補ããããããšãªãã³ ãã®è©Šè¬ã¯åžè²©ãããŠãããåå®éçãã¹ã
ã¢ãŒãããã³å®éçãã¹ãã¢ãŒãã®äž¡æ¹ã«äœ¿çš
ããããåå®éçã¢ãŒãã§ã¯ç¹ç°çæšèæäœçµ
åãè©äŸ¡ããããã«ãæ£è ã®ãªã³ãçäžã«ååš
ããããšãªãã³ãžã®æšèããããšãªãã³æäœã®
çµåãè©°æçã«é®æããããã«é«æ¿åºŠã§äœ¿çšã
ããããŸãå®éçã¢ãŒãã§ã¯ãªã³ãçã«çµåã
ãããšãªãã³ã®çµ¶å¯Ÿå€ã決å®ããããã®æšæºæ²
ç·ãåŸãããã«ã€ã ãã©ãžãªã¡ããªãã¯ã¢ãã»
ã€ïŒIRMAïŒãšã®é¢é£ã«ãããŠçš®ã ã®æ¿åºŠã§äœ¿
çšãããã (4) åºå®ãããããããšãªãã³æè¡æž ãã®è©Šè¬ã¯ãªã³ãçã«çµåããããšãªãã³ã®
å€ãå€æ¿æ³ã«ãã€ãŠæšå®ããããã®æšæºæ²ç·ã
åŸãããã«äžèšè©Šè¬ïŒããã³ïŒãšã®é¢é£ã«ãã
ãŠäœ¿çšãããå¶åŸ¡åã¬ã©ã¹ã®ãããªåºäœã«å ±æ
çµåããããããšãªãã³æè¡æž ãããªã€ãŠã
ãã 以äžã«è¿°ã¹ããã¹ãã§ã¯ãã®è©Šè¬ã¯ç²åãµã€
ãº1ÎŒãæ°åãµã€ãº550â«ã®ã¢ãªã«ã¢ãã³ã®å¶åŸ¡
åã¬ã©ã¹ã䜿çšããŠèª¿è£œããã ãã®ã¬ã©ã¹ããŸã2Nã®å¡©é žãšäºç¡é žãããª
ãŠã ïŒâã§æŽ»æ§åããã20ååŸã«ãã®ã¬ã©ã¹ã
èžçæ°Žã§å åæŽã€ãã次ã«ãã®ã¬ã©ã¹ïŒïœåœã
ãïŒmlã®ä¿åããããšãªãã³æè¡æž ãå ããã
PHã8.4ã«èª¿æŽããïŒâã§äžæ©åå¿ããããã
ã®åºå®ãããæäœãPH7.0ã®0.1Mãªã³é žç·©è¡æ¶²
å ã§å åæŽãã0.1ïŒ ã®BSAãå«ãPH7.0ã®
0.01Mãªã³é žç·©è¡æ¶²å ã«æçµæ¿åºŠ20mgïŒã¬ã©
ã¹ïŒïŒmlã§ïŒâã§ä¿åããã 以äžæ¬çºæã®æ¹æ³ãå®æœããããã®äžèšåè©Šè¬
ã䜿çšãããã¹ãã¢ãŒãã«ã€ããŠè©³çŽ°ã«èª¬æã
ããäžè¬ã«ãäžèšè©Šè¬ïŒãïŒãïŒïŒæšèãããã
ããšãªãã³æäœãããšãªãã³éœæ§ãªã³ãçããã³
粟補ããããããšãªãã³ïŒã¯åå®éç枬å®ãè¡ãª
ãã®ã«äœ¿çšããããŸãïŒã€ç®ã®åºå®ãããããã
ãšãªãã³æè¡æž ãå«ãå šãŠã®äžèšè©Šè¬ã¯ãªã³ãç
ã«çµåããããšãªãã³ã®å®éã«äœ¿çšãããã å®éçãã¹ããåå®éçãã¹ãã®ããããå¿ èŠ
ã§ããã«ããŠãããã¹ãæåã¯æ£è ã®æ«æ¢¢è¡æ¶²å
æ žçŽ°èãç¹ã«ãªã³ãçã®ãµã³ãã«ã§ããã泚ææ·±
ãåæããã°æ£è ã®å šãŠã®çœè¡çã®ãµã³ãã«ïŒäŸ
ãã°ççæ§çç®ïŒã䜿çšã§ãããšæãããããã
ãã§ã¯ç¬¬ïŒã®ã¹ããããšããŠæ«æ¢¢è¡æ¶²åæ žçŽ°èã®
ä»ã®è¡æ¶²æåããåé¢ããæ¹ãè¯ãããã®æ«æ¢¢è¡
液åæ žçŽ°èãšä»ã®è¡æ¶²æåãšã®åé¢ã¯å ¬ç¥ã®æ¹æ³
ã«ãã€ãŠè¡ãªãããšãã§ãããäŸãã°åæ žçŽ°èã»
ãã¬ãŒã¿ãŒã䜿çšããã°ãããã«ãŒãã©ãŒ
ïŒLudererïŒçã®ãRapidãQuantitatine Human
Lymphocyte Separation and Purification in
ïœ Closed SystemãïŒMolecular Immunol.ã
16ã621ïŒ1979ïŒãããã¯ãã€ã ïŒBoyumïŒã®
FicollâHypaqueæ³ïŒScand.J.Immunol.ãïŒïŒå¢
åïŒïŒãïŒïŒ1976ïŒïŒãåç §ãããããé å¿æ²æŸ±ç
ã®å ¬ç¥ã®æ¹æ³ã«ããæŽæµãããã³è¡çèšç®åšä¹è³
èªåè¡çã«ãŠã³ã¿ãŒã«ããèšæ°ã«ãã€ãŠçŽ°èæ°ã
èŠæ Œåããããšã§æ¬çºæã®æ¹æ³ã®æºå段éãçµäº
ãããå¿ ããå¿ èŠãªãã®ã§ã¯ãªãããæ«æ¢¢åæ žçŽ°
èã®ãªã³ãçãã©ã¯ã·ãšã³ãå ¬ç¥ã®æ¹æ³ã§åŸãŠã
ã¹ããµã³ãã«ãšããŠäœ¿çšããããšãã§ããã åå®éçã¢ãŒãã«ãããŠã¯ãåèšãªã³ãçã®äž
å®éãæšèããæããããšãªãã³æäœã®äžå®éãš
æ··åããããã®ãšãäžå®éã®ç·©è¡æ¶²ãæ··åããã®
ãæãŸãããå¥ã«ããã®æ£è ã®ãªã³ãçãæšèã
ãæããããšãªãã³æäœããã³äžå®éã®ç²Ÿè£œãã
ããããšãªãã³ïŒããã¯ç·©è¡æ¶²ã®æ¿ãã«ããªããïŒ
æ··åããŠéåžžã®è©°æçãã¹ãçµååç §ãšãããã
ãã¯ããããšãªãã³ãæšèããæäœã®ãã¹ã现è
ãžã®ã©ã®ãããªç¹ç°ççµåãè©°æçã«ãã¬ããã
èšæ°ãããç¹ç°ççµåãšããŠå ±åãããåå®éã®
çµæã¯ããå ããéå°ã®ããããšãªãã³ãã®éå
åšäžã§ã®cpmïŒïŒåéåœãã®èšæ°ïŒçµåãã枬å®
ç³»ã«å ããããI125ã§æšèããæäœã®ç·éã®cpm
ããå ããããéå°ã®ããããšãªãã³ã®ååšäžã§
ã®çŽ°èãžã®cpmçµåãåŒãããã®ã§å²ã€ãå€ãã
éå°ã®å¯æº¶æ§ããããšãªãã³ã®ååšäžã§ã®çŽ°èãž
ã®cpmïŒïŒåéåœãã®èšæ°ïŒçµåãåŒãããšã«ã
ã€ãŠæ±ºå®ãããããã®ãå ããããéå°ã®ããã
ãšãªãã³ããšã¯æšèããæäœã®çŽ°èãžã®ç¹ç°ççµ
åãå®å šã«é®æããããã«æž¬å®ç³»ã«å ããããå¯
溶æ§ããšãªãã³ã®ç·éãšããŠå®çŸ©ãããã äžè¬ã«ãç¹ç°ççµåã¯å°ãªããšãïŒã€ã®ç°ãªã
现èæ¿åºŠã§è©äŸ¡ããããçµæã¯ç¹å®çŽ°èæ°åœãã®
æ«æ¢¢è¡æ¶²ãªã³ãçãžã®cpmãããã¯çµåçã§å ±å
ããããé®æãããããªé«æ¿åºŠã§å ãããããã
ã§ããã第ïŒæ®µéã¯ïŒç¬¬ïŒæ®µéãšãã€ãŠãŠããã¡
ããäžèšãã¹ãã®åã§ãåŸã§ããŸãåæã«ã§ãå·®
ãæ¯ããªããïŒäžèšïŒã€ã®æäœããã¹ã现èã®æ¿
ãã«ããšãªãã³éœæ§ãªã³ãçã䜿çšããŠè¡ãªãã
枬å®ç³»ã®æ©èœæ§ãšæšèããæäœã®å®å®æ§ãã¢ãã¿
ãŒããããšã§ããããã以äžã®ããšãã¯ãå¿ èŠã§
ããå Žåã«ã¯ä»»æã®ã¹ããããšããŠãããšãªãã³
éœæ§ãªã³ãçã®æ¿ãã«å¯Ÿç §é°æ§çŽ°èã䜿çšããŠç¬¬
ïŒæ®µéãšåãæäœãããŠãããããã®å¯Ÿç §é°æ§çŽ°
èãšããŠã¯çã®è¡æž ã¢ã«ããã³ãæ ãCCLâ119
ãªã³ãçã®ãããªãæšèããæäœãšåå¿ããªãè
çœãæ ããã®ã䜿çšããã é©åœãªå¹é€æéã®åŸãåèšçŽ°èãæŽã€ãŠé å¿å
é¢ãããäžæŸãååããŠãã¬ããåãã现èã®çµ
åæšèãè©äŸ¡ãããI125ã§æšèããæäœã䜿çšã
ãå Žåã«ã¯Î³ç·ã¹ãã¯ããã¡ãŒã¿ãŒå ã§å®éç枬
å®ã«ãããŠã¯æ£è ã®ãªã³ãçãšå®æ§å¯Ÿç §ãªã³ãç
ã®æž¬å®ãäžè¿°ãšåæ§ã«ããŠè¡ãªããããã«ããã
ãšãªãã³ãéãå¢ããªããäžå®æ¿åºŠã®åºå®ããã
æããããšãªãã³æè¡æž ïŒIMAïŒãšãšãã«å¹é€
ããŠæšæºæ²ç·ãäœæããããã®ç³»ã§ã¯IMAããŸ
ãç·©è¡æ¶²ã®ã¿ãšæ··åãããããããã¯çš®ã ã®æ¿åºŠ
ã®ããããšãªãã³ãšæ··åããããã¹ã现èãåæ
ããã®ã«äœ¿çšããã®ãšåãæçµçãªæéééãŸã§
äžå®æéééã§æšèããæäœãå ããŠå¹é€ãç¶ã
ãããã®IMAãç·©è¡æ¶²ã§æŽã€ãŠãé å¿æ²æŸ±ã«ã
ã€ãŠãã¬ããåãããäžæŸããã«ã³ãããŠããã¬
ããã®æŸå°ç·æŽ»æ§ãè©äŸ¡ãããåããããšãªãã³
æ¿åºŠã«ã€ããŠç¹ç°ççµåããç·©è¡æ¶²ã®ã¿ãååšã
ããšãã®IMAãžã®cpmçµåãã次第ã«éãå¢ã
ããå ããããããšãªãã³ãã«ãããå ããæäœ
ã®ç·cpmãšcpmçµåã®äž¡æ¹ããåŒã以å€ã¯äžèšãš
åæ§ã«ããŠæ±ºå®ãããç察æ°æ¹çŒçŽã®çŽç·ç®çã«
ç¹ç°ççµåããšãã察æ°ç®çã«å ããããšãªãã³
ã®éããšã€ãŠããããããŠæšæºæ²ç·ãäœæããã
æ£è ã®çŽ°èã«ããç¹ç°ççµåã察æ°ç®çã«å€æ¿ã
ãããšã«ãã€ãŠæ£è ã®æ«æ¢¢è¡æ¶²ãªã³ãçã«çµåã
ãããšãªãã³ã®å®éããªããããä»ã®ãšããã§
ã¯ããã®æšæºæ²ç·ã¯æ£è ã®ãã¹ãã«äœ¿çšããã®ãš
åãããããšãªãã³ã䜿çšããŠæ£è ã®ãã¹ãã®éœ
床äœæããæ¹ãè¯ããšæããããèŠæ Œåãšè²¯èµå¯¿
åœããªãã¡å®å®æ§ãæ¹è¯ãããã°ãæšæºæ²ç·ã®äœ
æã¯ãããªã«é »ç¹ã«è¡ãªããªããŠãããªãã§ãã
ãããã¡ãããã¢ã€ãœããŒãã䜿çšããå Žåã«ã¯
ãã®éœåºŠæšæºæ²ç·ãäœæããªããã°ãªããªãã ãã¡ããäžèšåã¢ãŒãã«ãããŠãè©Šè¬ãšãã¹ã
çµæã確èªããããããšãªãã³éœæ§ãªã³ãçã䜿
çšããåèšç¬¬ïŒæ®µéã®æž¬å®ã§åŸãããçµæã䜿çš
ããŠåãèšç®ããªãããã åŸã«è©³çŽ°ã«èª¬æããããã«ãããã§èª¬æããã
ã¹ãæ¹æ³ã¯ã¬ã³ã®æ©æçºèŠããã³æ²»çå¹æãã¢ã
ã¿ãŒããæå¹ãªæ段ãšããŠäœ¿çšããããšãã§ã
ããæ£åžžãªå¥åº·äººã®å Žåã«ã¯ã粟補ããããããš
ãªãã³ãååšããå Žåãšååšããªãå Žåã®çµåæš
èã®æž¬å®å€ã«ã¯æ®ã©å·®ããªããããã€ãŠãå°ãã
ããåæã®ïŒç å以åã®ïŒã¬ã³ãããã¯é²è¡ãã
ã¬ã³ã®æ£è ã®æ«æ¢¢è¡æ¶²ãªã³ãçã®å Žåã«ã¯ããã
ãšãªãã³ãååšããªãç³»å ã®çµåæšèãå¢å ã
ãã 次ã«ãåè¿°ããè©Šè¬ã䜿çšãã枬å®æ¹æ³ãäŸã
æããŠæŽã«è©³çŽ°ã«èª¬æããã åè¡ãææ¢ãããè¡æ¶²èŠæ¬ããåè¿°ã®ãã€ã ã®
æ¹æ³ã«ãã€ãŠãªã³ãçãåé¢ããããã®ãšããªã³
é žå¡©ã§ç·©è¡ããçççé£å¡©æ°Žã§ãã®èŠæ¬ãïŒïŒïŒ
ã§åžéãããã®è¡æ¶²ããã€ã³ã«âãã€ããã¯
ïŒFicollâHypaqueïŒæº¶æ¶²äžã«å±€ããªãããã«é
ãã«æ³šãã ã次ã«400Ãïœã§30åéé å¿æ²æŸ±ãã
ããšãããªã³ãçãæ確ãªçé¢ãæã€ãŠåž¯ç¶ããª
ãããããããã¹ããŒã«ããããã§åãåºããç·©
ãããªé å¿æ²æŸ±ïŒ200Ãïœã10åéïŒã«ãã€ãŠ
PBSå ã§ïŒåºŠæŽã€ããããã«ããããïŒÃ107
åïŒmlã®æ¿åºŠã§0.1ïŒ ã®BSAãš0.02ïŒ ã®ã¢ãžåã
ããªãŠã ãå«ãPBSä¹è³RPMIå¹é€åºå ã«æžæ¿ã
ãããå¯Ÿç §éœæ§çŽ°èïŒããšãªãã³ãæ ããªã³ã
çïŒããã®æ¿åºŠã§æžæ¿ãããã å现èæ¿åºŠã«ãããŠãã¹ãããåèŠæ¬ã«ïŒæ¬ã®
12Ã75mmã®ãã©ã¹ããã¯è©Šéšç®¡ãå²ãåœãŠããïŒ
âã®æ°ŽæµŽã®äžã§åå¿ãéå§ããããåè©Šéšç®¡ã«
100ÎŒã®çŽ°èãå ãããåçµã®æåã®ïŒæ¬ã®è©Š
éšç®¡ã«ã¯ããã«100ÎŒã®PBSâBSAâã¢ãžåç©
溶液ãå ããæ®ãã®ïŒæ¬ã®è©Šéšç®¡ã«ã¯10ã50ÎŒ
ïœïŒmlã®æ¿åºŠã§ïŒéå°ã®HFïŒPBSâBSAâã¢ãž
åç©æº¶æ¶²ã«å ããããããããšãªãã³100ÎŒã
泚ãã ããã®æ¿åºŠã¯ïŒÃ106åã®éœæ§å¯Ÿç §çŽ°èãž
ã®I125æšèã®æäœã®ç¹ç°ççµåãé®æããã®ã«å
åã§ãã€ãã100ÎŒã®I125æšèæäœïŒ50000ã
100000opmïŒãå ããåŸããã®è©Šéšç®¡ãã·ãšãŒã«
ãŒæµŽã«ç§»ããŠïŒâã§äžæ©ïŒ16ã18æéïŒå¹é€ããŠ
çµåã平衡ã«éãããããå¹é€ã®åŸãïŒmlã®
PBSã§çŽ°èãæŽãã3000rpmã§15åéé å¿æ²æŸ±ã
ãããäžæŸãã¢ã¹ãã¬ãŒãããŠã现èãã¬ããã®
çµåæŸå°æŽ»æ§ãèšæ°ããããã®ããã«ããŠåŸãç¹
ç°ççµåã®å埩詊éšã«ãã€ãŠåŸãå€ãå¹³åããã ããããšãªãã³ã®ã»ãŒå®å šãªçµåé®æäœçšã«ã
ã€ãŠãã¹ã现èã«çµåããããšãªãã³ã«å¯Ÿããæš
èããšãªãã³æäœã®ç¹ç°æ§ã確ç«ããããšãšã
ã«ã现èè¡šé¢ãžã®éç¹ç°çåžçãäœã¬ãã«ã«ä¿ã
ããã 次ã«æ¬çºæã®æž¬å®æ¹æ³ã®æ¥µããŠé«ãæ床ã«ã€ã
ãŠèª¬æããã ãªã³ãçäžã®ããšãªãã³ã枬å®ãåŸãæ床ã®äž
éãããããšãªãã³ã®æ¿åºŠãå¢ããªãããäžå®æ¿
床ã®æŸå°ç·æšèããããšãªãã³æäœãš2.5Ã105ã®
éœæ§å¯Ÿç §çŽ°èïŒæ確ãªéã®ããšãªãã³ãæ ã€ã
CCLâ119ïŒã䜿çšããŠè©°æçµåã«ãã€ãŠæ±ºå®ã
ããæ€åºã®äžéã¯ïŒã2.5Ã19-9ïœããããã¯4.4
ã5.5Ã10-6ããã¢ã«ã§ããããšãåãã€ããã
ã®äžéã¯æŸå°ç·æšèããããšãªãã³æäœã®éœæ§å¯Ÿ
ç §çŽ°èãžã®ç¹ç°ççµåãåçŸå¯èœã«çŠæ¢ãåŸãã
ãããšãªãã³ã®æå°éã«åºã¥ããã®ã§ããã é°æ§çŽ°èã®éå£å ã®ããšãªãã³ãæ ã现èã®æ€
åºå¯èœãªæå°ã®æ°ãæçµçŽ°èæ°2.5Ã105åãšãªã
ããã«é°æ§çŽ°èãšæ··åããå¯Ÿç §éœæ§çŽ°èã䜿çšã
ãŠç 究ããããã®çŽ°èå¯åºŠã«ãããŠã12500åã®
现èãïŒïŒ ç¹ç°ççµåã®èå¥ã¬ãã«ã§æ€åºããã
ãšãã§ãããåèšå®éããŒã¿ããèŠããšãããã¯
æ€åºã®äžéã§ããããšãªãã³ã®çµ¶å¯Ÿå€çŽ2nïœã«
察å¿ããŠããããããã€ãŠçŽ°èæ°ïŒÃ106ã®éå£
ã®å Žåã«ã¯1.25ïŒ ã®éœæ§çŽ°èãæ€åºãåŸããšèã
ããããæç®ã«ããã°ãªã³ãçã®ç·æ°ã®ãã¡16.6
ïŒ ãããšãªãã³éœæ§çŽ°èã§ãããšãããšä¹³ããã®
城åããããšãããŠããããïŒã¢ããçã®
ãCancer Immunol.Immunother.ããïŒã101
ïŒ1977ïŒïŒããã¯æ¥µããŠçŽ æŽãããå€ã§ããã 次ã«å®éçãªæž¬å®ã«ãããŠæšæºæ²ç·ãäœæãã
äžè¬çãªæ¹æ³ã説æããã è€æ°ã®å šãåã12Ã75mmã®è©Šéšç®¡ã«ä¿åIMA
ïŒã¬ã©ã¹20mgïŒmlïŒããåãåºããŠPBSâBSAâ
ã¢ãžåç©æº¶æ¶²ã§äºãïŒïŒ10ã§åžéããããããšãª
ãã³æè¡æž IMA100ÎŒãå ãããåã»ããã®è©Š
éšç®¡ã«100ÎŒã®ç·©è¡æ¶²ãåç¬ã§å ãããããã
ããšãªãã³ãç·©è¡æ¶²ã§çš®ã ã®éã«åžéãããã®ã
å ããããã®æž¬å®ã¯ïŒâã®æ°ŽæµŽå ã§éå§ããã次
ã«ãã®è©Šéšç®¡ãã·ãšãŒã«ãŒæµŽå ã§30åé22âã«ä¿
ã€ããã®æéã®çµãã«æŸå°ç·æšèããããšãªãã³
æäœïŒ100ÎŒïŒIMAãå ¥ã€ãåè©Šéšç®¡ã«å ãã
æŽã«30åéä¿æž©ãç¶ããããã®è©Šéšç®¡ãéœæ§å¯Ÿç §
èŠæ¬ãšåãæ¹æ³ã§æŽã€ãŠé å¿æ²æŸ±ããããå¯Ÿç §èŠ
æ¬ã®å Žåãšã¯ç°ãªããæŸå°ç·æšèããæäœã¯æž¬å®
ã®éå§æã«ã¯å ãã30ååŸã«å ãããããã«ãã€
ãŠæšèããæè¡æž ãå ããåã«ããããšãªãã³ã
IMAæè¡æž ãšå¹³è¡¡ã«éããããšãã§ããããã
ããªããå¹é€æéãé©åœã§ããã°æšèããæäœã
åæã«å ããããšãã§ããã çš®ã ã®æ¿åºŠã«åžéããéœæ§å¯Ÿç §çŽ°èã«å¯Ÿããç¹
ç°ççµåãæšæºæ²ç·ããå€æ¿ããããšã«ãã€ãŠã
ãšãªãã³çµåã®çµ¶å¯Ÿéã決å®ããããšãã§ããã 第ïŒè¡šã¯æ¬çºæã®åå®éã¢ãŒãã®æž¬å®æ¹æ³ã«ã
ã€ãŠå€æ°ã®æ£è ããã¹ãããçµæã瀺ããã®ã§ã
ããæ£ç¢ºåºŠããã³æ£è ã®çš®é¡ã¯ä»ã®èšºææ¹æ³äŸã
ã°çäœçµç¹æ€æ»ã«ãã€ãŠæ±ºå®ããã
ã³ãã€ãžãšã³ãååšãããã©ããã決å®ããæ¹æ³
ããã³è£ 眮ãç¹ã«è©Šè¬ã®ç掻åãããšãã¯ããæ
段ãšè©Šéšã®ä¿¡é Œæ§ãäžããããã«ç¹æ®ãªéœæ§å¯Ÿç §
ã䜿çšããæåâæäœã¿ã€ãã®å ç«æž¬å®æ¹æ³ã®æ¹
è¯ã«é¢ãããã®ã§ããã ç±³åœç¹èš±ç¬¬4116776å·ã«ã¯äººéã®èç€ãã«ã¢ã³
ïŒhCGïŒããªã³ãçäžã«ååšãããã©ããã決å®
ããæ¹æ³ãé瀺ãããŠããããã®æ¹æ³ã¯ã¬ã³ã®æ€
æ»ãšããŠã®ç·æ§ããã³åŠåš ããŠããªã女æ§ã®hCG
ã®æ€åºæ¹æ³ãæ¹è¯ãããã®ã§ããããã®ç¹èš±ã®çº
æè ã¯è¡æž äžã®hCGã®æç¡ãæ€æ»ããããã®åŸæ¥
ã®ã©ãžãªã€ã ãã¢ãã»ã€ãã¹ãã«èšåãã宿䞻ã®
ãªã³ã现èãæªæ§ã®è «ç现èã«ãã€ãŠåæ²ããã
hCGãéããŠãã®hCGãšçµåããããšãçºèŠãã
ãšèšã€ãŠããããããŠãã®ç¹èš±ã®è©Šéšã¯åŸæ¥ã®è¡
æž è©Šéšã«æ¯ã¹ãŠæ床ãé«ãããšãç¹åŸŽãšãããã®
ã§ãããšè¿°ã¹ãŠããããã®ç¹èš±ã®æ¹æ³ã«ãããŠ
ã¯ãåèšãªã³ãçã«çµåããhCGååããã·ã¢ãª
ã³é žæ®æ»ãé€å»ããåŸããã®ãªã³ãçãhCGã®ãµ
ããŠãããã«ç¹ç°çãªæšèããæè¡æž ã«ãããã
平衡ã«éããåŸã«ãã®æšèãäŸãã°è¢å ãæŸå°æŽ»
æ§ãã®éã枬å®ããããšã«ãã€ãŠhCGã®æ¿åºŠã枬
å®ãããæ¢ç¥ã®å¥åº·äººã®è¡æ¶²ãåãæšèã«ã€ãã
ããéžæãããéç¹ç°çæè¡æž çã®é°æ§å¯Ÿç §ãã
ãã®æ¹æ³ã§ã¯éåžžçšããããã ç±³åœç¹èš±ç¬¬3988115å·ã«ã¯ãããªã¬ã³ãã«çµå
ããããšã®ã§ãããªã³ãçã®éã決å®ããè©Šéšã
é瀺ãããŠããããã®è©Šéšã¯ãã®ãªã¬ã³ãã«ç¹ç°
çãªã¬ã»ãã¿ãŒãæãããªã³ãçãšçžäºã«äœçš
ãããã®ç¹ç°çãªã¬ã»ãã¿ãŒãæãããªã³ãçã®
ã¿ã®å¢çãåºæ¿ãããªã¬ã³ãã«åºã¥ããã®ã§ã
ãããã®ãªã¬ã³ãã«ç¹ç°çãªã¬ã»ãã¿ãŒãæãã
ãªã³ãçã®éãæ€åºããã®ã«æšèãããªã¬ã³ãã
䜿çšãããããã®è©Šéšã®é·æã¯è¡æµäžã«å€éã®æ
äœãååšããåã§ã䜿çšã§ããããšã§ãããšäžèš
ç¹èš±ã«ã¯èšèŒãããŠãããã²ã«ããŒãºã«åžåãã
ãæäœçã®æå®ã®ãªã¬ã³ãçµå掻æ§ãæããç²å
ãããã¯æ£åžžäººã®è¡æ¶²ãå¯Ÿç §ãšããŠäœ¿çšãããã ããã³ãïŒRockoffïŒçã®ãSensitive and
Covenient Quantitation of Antibody Binding
to Cellular Antigens Using Glutaraldehyde
Preserved CellsãïŒJournal of Immunological
Methodsã26ã369ã1979ïŒã«ã¯ã°ã«ã¿ã«ã¢ã«ã
ããåºå®ããæšç现èã䜿çšããŠã¬ã³ã«ç¹ç°çãª
æäœãæ€åºããå®éããæ¹æ³ãèšèŒãããŠããã
å¯Ÿç §ã¯æ£åžžè¡æž ãšæ¶²äœå¹å°ã§ããã ããã·ãžãŠãã€ïŒTomasiãJr.ïŒã®
ãStructure and Functions of Alphaâfetopâ
roteinãïŒAnn Rev.Med.ã1977ã28ïŒ453ïŒã«
ã¯ãæè¬ãã¬ã³ã«ãããæã家æãã®æ«æ¢¢åæ žè¡
çã®è¡šé¢ã«ã¯ã¢ã«ãã¢èå èçœè³ªïŒAFPããªã³
ã³ãã€ãŒã¿ã«ïŒoncofetalïŒã¢ã³ãã€ãžãšã³ã®äž
çš®ïŒã®çºççãé«ãããšãèšèŒãããŠãããæ¬çº
æè ã®åŸãæ å ±ã«ããã°ãããã·ãžãŠãã€ã¯è¢å
å ç«æž¬å®æ³ã«ãã€ãŠãæAFPæäœã®åç¹ç°æ§ã
ã©ã°ã¡ã³ããååŠçã«ãã«ãªã¬ã»ã€ã³ã«çµåã
ãããããæ£è ã®ãªã³ãçãšãšãã«å¹é€ããåŸã
é¡åŸ®é¡äžã§éœæ§çŽ°èãèšæ°ããã ããŒãã³ïŒNaughtonïŒçã®ãLocalization of
the β Chain of Human Chorionic
Gonadotropin on Human Tumor Cells and
Placental CellsãïŒCancer Researchã35ã1887
ïŒ1975ïŒïŒã«ã¯é µçŽ æšèããhCGæäœã䜿çšããŠäºº
éã®è «ç现èã®è¡šé¢äžã«hCGãäœçœ®ãããããšã
èšèŒãããŠããã ããïŒã€ã®ãªã³ã³ãã€ãŒã¿ã«èçœã§ããããšãª
ãã³ã¯æœå¢è «çããŒã«ãŒã§ããããšãç¥ãããŠã
ããããŒã«ã¹ïŒMarcusïŒçã®ãSerum Ferritin
Levels in Patients with Breast Cancerã
ïŒClin.Res.ã23ã447ïŒ1975ïŒïŒã«ã¯äºéæäœã©ãž
ãªã€ã ãã¢ãã»ã€æ³ã«ãã€ãŠè¡æž ããšãªãã³ã枬
å®ããããšãèšèŒãããŠãããããã«å¯ŸããŠã¢ã
ãïŒMorozïŒçã®ããæè¿ã®è«æã«ããã°ãã
ãç¹ç°çãªæªæ§è «çããŒã«ãŒã¯ããšãªãã³ãæ ã€
ããªã³ãçã®ååšã§ãããïŒãLymphocytes
Bearing Surface Ferritin in Patient with
Hodgkinâ²s Disease and Breast CancerãâThe
New England Journal of Medicineã
correspondenceã276ãNo.20ã1172ïŒ1977ïŒãã
ã³ãFerritinâBearing Lymphocytes and â
cell Levels in Peripheral Blood of Patients
with Breast CancerãâCancer Immunol.
Immunother.ãïŒã101ïŒ1977ïŒåç §ïŒã¢ããçã¯
ããšãªãã³ãæ ã€ã现èã決å®ããã®ã«çŽ°èå·å®³
ãã¹ããçšãããããªãã¡æ£è ã®ãªã³ãçã«æäœ
ãå ããåŸãè£äœãå ããŠè¡šé¢ã«æäœãæããªã
现èãç Žå£ããæ»ãã 现èã«ãã€ãŠã¯æé€ãããª
ããããªã¿ã€ãã®æšæºçãªè²çŽ ãçšããŠæ»ãã 现
èã®æ°ã決å®ããã æ¬çºæã¯æ«æ¢¢è¡æ¶²ãªã³ãçäžã®å°ãªããšãïŒçš®
ã®ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãæ€åºããã
ãšã®ã§ããè¡æ¶²ãã¹ãæ¹æ³ãæäŸããããšãç®ç
ãšãããã®ã§ããã ããã«æ¬çºæã¯æ«æ¢¢è¡æ¶²ãªã³ãçäžã®ããšãªã
ã³ãæ€åºããããã®è¡æ¶²ãã¹ãæ¹æ³ãæäŸããã
ãšãç®çãšãããã®ã§ããã ããã«æ¬çºæã¯å°ãªããšãïŒã€ã®ããšãªãã³ç
ã®ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãæ ãæ«æ¢¢è¡
液ãªã³ãçã®éšåæ¯éå£ãå®éããæ¹æ³ãæäŸã
ãããšãç®çãšãããã®ã§ããã ããã«æ¬çºæã¯æ«æ¢¢è¡æ¶²ãªã³ãçäžã®ãªã³ã³ã
ã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã®æç¡ãå®éçä¹è³åå®
éçæ¹æ³ã§æ±ºå®ããããšãã§ãããã€ãã®ãã¹ã
ã®æå¹æ§ã確èªããã®ã«ãªã³ãçã«ä»çãããã
ãããªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãããªãéœ
æ§å¯Ÿç §ã䜿çšããããã«ããæšèåŒã®æ¹è¯ããã
å ç«æž¬å®æ¹æ³ãæäŸããããšãç®çãšãããã®ã§
ããã ããã«æ¬çºæã¯å°ãªããšãããçš®ã®ã¬ã³ãæ©æ
çºèŠä¹è³äºç¥ããããšã®ã§ããæšèåŒã®å ç«æž¬å®
æ¹æ³ãæäŸããããšãç®çãšãããã®ã§ããã ãŸãæ¬çºæã¯äžèšã®ãããªæ¹æ³ãå®æœãããã
ã®è£ 眮ããªãã¡è©ŠéšããããæäŸããããšãç®ç
ãšãããã®ã§ããã æ¬çºæè ã¯æ«æ¢¢è¡æ¶²åæ žçŽ°èïŒperipheral
blood mononuclear cellïŒãäŸãã°ãªã³ãçäžã®
å°ãªããšãïŒã€ã®ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãš
ã³ã次ã®ãããªæ¹æ³ã«ãã€ãŠåå®éçä¹è³å®éç
ã«æ€åºã§ããããšãçºèŠããã (A) æ£è ã®æ«æ¢¢è¡æ¶²åæ žçŽ°èã®äžå®éããã®ãªã³
ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã«å¯Ÿããæšèãã
æäœãšæ··åããåã现èãµã³ãã«ã®æ¬¡ã®äžå®é
ããè©°æççµåé»å®³éã®ç²Ÿè£œããããã®ãªã³ã³
ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãå ããæšèããæ
äœãšæ··åããã (B) 次ã«ãæ¢ç¥ã®æåâéœæ§ã®æ«æ¢¢è¡æ¶²åæ žã¿ã€
ãã®çŽ°èãåèšæ£è ã®çŽ°èãµã³ãã«ã®æ¿ãã«äœ¿
çšããŠã(A)ãšåãæäœãããã次ã«ä»¥äžã«è©³è¿°
ãããããªèšç®ãè¡ãªãã å®éãè¡ãªãå Žåã«ã¯ãïŒçªç®ã®è©Šè¬ãããªã
ã¡ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã«åºå®ããã
æäœãåèšæšèããæäœããã³ç²Ÿè£œããæåãšãš
ãã«äœ¿çšããŠäžé£ã®æšæºæ²ç·ãäœæããã æ¬çºæã®äžå®æœäŸã«ãããŠã¯åèšãªã³ã³ãã€ãŒ
ã¿ã«ã¢ã³ãã€ãžãšã³ã¯ããããšãªãã³ã§ãããæ
äœã¯ãã¡ããæããããšãªãã³ã§ãããæŸå°æŽ»æ§
ãšãŠçŽ ãäŸãã°I125ã§æšèããã®ãæãŸããã æ¬çºæã¯ããã«æ¬çºæã®æ¹æ³ã«äœ¿çšãããè©Šè¬
ãå¥ã ã«å容ããè©Šè¬ãããããæäŸãããã®ã§
ããã 以äžæ¬çºæãæŽã«è©³çŽ°ã«èª¬æããã éå»æ°å¹Žã«äºã€ãŠãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãž
ãšã³ãæ€åºããå®éããããšããçååŠçãªç 究
ãå€ããªãããããã«ãªã€ãŠããããªã³ã³ãã€ãŒ
ã¿ã«ã¢ã³ãã€ãžãšã³ã¯éåžžã¯èå å ãããã¯ãæ£
åžžãªåŠå©Šå ã«hCGãååšããããã«ããéæªæ§ã®
ççåŠçæ¡ä»¶ã«ããæ人å ã«ã®ã¿å€éã«ååšã
ããããããªããã¬ã³ã«ããã€ãŠããããããã¯
ã¬ã³ã®çŽ å ãæããæ人ã«ããªã³ã³ãã€ãŒã¿ã«ã¢
ã³ãã€ãžãšã³ãååšããããšã次第ã«æããã«ãª
ã€ãŠæ¥ããããã§åé¡ãšãªãã®ã¯äžèšä»¥å€ã®çç
åŠçæ¡ä»¶äžã«ããæ人ã«ãäžè¿°ã®ããã«ãªã³ã³ã
ã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãååšããããšã§ããã
äŸãã°æ¶å管ã®ççæ§çŸç ã«ããã€ãŠããåŠåš ã
ãŠããªã女æ§ã®è¡æž äžã«ã¯hCGãååšããããæ¥
æ§èçãæ ¢æ§èèç害çã®æ£è ã®è¡æž äžã«ã¯ã¢ã«
ãã¢èå èçœè³ªãååšãããæè¿ã®ç 究ã«ãã€ãŠ
è¡æž ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãšæ«æ¢¢è¡æ¶²
åæ žçŽ°èã«çµåãããªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãž
ãšã³ã®åºå¥ãã€ãããã«ãªã€ãããšãããè«æã«
èšèŒãããŠããããã®è«æã«ããã°ãæªæ§ã®ç¶æ
ã«ãããããããã¯ãã®çŽ å ãæããç¶æ ã«ãã
ãšè¡æž äžã«ã§ã¯ãªãæ«æ¢¢è¡æ¶²åæ žçŽ°èã®è¡šé¢ã«å€
éã®ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãçºèŠãã
ããããã«ããã®è«æã¯ããªã³ã³ãã€ãŒã¿ã«ã¢ã³
ãã€ãžãšã³ãæ ãæ«æ¢¢è¡æ¶²åæ žçŽ°èã®éšåæ¯éå£
ã¯ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã®è¡æž ã¬ãã«
ãšã¯ç¡é¢ä¿ã§ãããæªæ§ã®çŽ å ã®ååšã«é¢ä¿ãã
ããšã匷ã䞻匵ããŠããã å€ãã®ç 究è ã人ã®æ£åžžãåŠããšãããšãªãã³
ã®é¢ä¿ã«æ³šç®ããŠãããããšãªãã³ã¯ååéçŽ
450000ã®éã貯èµããèçœã§ãããããšãªãã³ã¯
å®éã«ã¯è€æ°ã®ãµããŠããããããªã€ãŠãããã
ãªãã¡ååéçŽ18000ã®è€æ°ã®ã€ãœããšãªãã³ã
éå ±æçµåã«ãã€ãŠäºãã«çµåãããã®ã§ããã
å°ãªããšããã®ãã¡ã®å¹Ÿã€ãã®ã€ãœããšãªãã³ã
äºãã«åé¢ããããšã¯çé»ç¹ãå©çšããã°å¯èœã§
ãããçé»ç¹ãçŽ4.3ã5.0ã§ããã€ãœããšãªãã³
ã¯ç¹ã«é¢çœããã§ãããã¢ã«ããŒãïŒAlpertïŒ
çã®ãCarcinoâFoetal Human Liver
FerritinsãïŒNatureã242ã194ïŒïŒæ16æ¥ã
1973ïŒïŒãåç §ããããã αâïŒââã°ãããªã³ã¯èå ã®èèå ã«äž»ã«
çºèŠãããé žæ§ã€ãœããšãªãã³ã§ãããïŒçš®ã®ãª
ã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã§ããããèèè «
çãå¥åœ¢è «çã®çš®ã ã®æªæ§çŸç ãæããæ人å ã«
ãçºèŠããããå ç«åŠçã«ã¯ãæ£åžžãªããããšãª
ãã³ãããŸã åºå¥ãããŠããªãã€ãœããšãªãã³ã
å€ããããããªãããå ç«åŠçãªæäœç£çææ³ã
䜿çšããã°äžèšÎ±âïŒââã°ãããªã³ã5.1ã
5.6ã®çé»ç¹ãæããã€ãœããšãªãã³çã®ç¹å®ã®
ã€ãœããšãªãã³ã«å¯Ÿããæäœã¯ç£çããããšãã§
ãããšèããããã äžè¿°ã®ãããªåœç¶èµ·ããççåŠççŸè±¡ãããªã
ã¡ãããªãåºãæ¿åºŠç¯å²ã«äºã€ãŠæ£åžžã®è¡æž äžã«
ããšãªãã³ãååšããããçŸåšã®ãšããç°ãªãã€
ãœããšãªãã³ãå ç«åŠçã«åºå¥ããããšãã§ã
ããããã«éæªæ§ã®è²§è¡ã®ãããªéæªæ§ã®çŸç ç¶
æ ã«ãããšè¡æž ããšãªãã³ã¬ãã«ãäžæããããš
ãèãåããããšè¡æž ããšãªãã³ã¬ãã«ã蚺æã®
åºæºãšããããšã¯å°é£ã§ãããããç 究ã§æªæ§ã®
çŸç ã«ããã€ãŠããæ£è ããã¹ããããšãããã®
çŽ70ïŒ ã®è¡æž ããšãªãã³ã¬ãã«ãäžæããŠããã
ããã«ãåæã®ä¹³ããæ£è ã«ãããŠã¯è¡æž ããšãª
ãã³ã¬ãã«ã¯æ£åžžãªè¡æž ã®ããšãªãã³ã¬ãã«ãšãª
ãŒããŒã©ããããŠããããåçºæ§ãããã¯è»¢ç§»æ§
ã®ä¹³ããã«ããã€ãŠãã女æ§ã¯è¡æž ããšãªãã³ã¬
ãã«ã極ããŠé«ããšããå ±åããããã€ã³ã
ïŒJacobsïŒçã®ãSerum Ferritin Concentration
in  arly Breast CancerãïŒBr.J.Cancerã34
(3)ã286ïŒ1976ïŒïŒããSerum Ferritin
Concentration in Untreated Hodgkinâ²s
DiseaseãïŒåæž34(3)ã162ïŒ1976ïŒããµãŒã·ãã³
ïŒSarcinoneïŒçã®ãIncreased Ferritin
Synthesis and Release by Hodgkinâ²s Disease
in Peripheral Blood LymphocytesãïŒInt.J.
Cancerã20ã339ïŒ1977ïŒïŒããã³æ°æŽ¥çã®
ãRadioimmunoassay of Serum Ferritin in
Patients with MalignancyãïŒAnn.N.Y.Acad.
Sciã259ã450ïŒ1975ïŒïŒãåç §ããããã ã¢ããçã®ç 究ã®äžéšãåè¿°ããããã¢ããç
ã¯ããã«ãããšãªãã³èçœæåãããžãã³æ°ãªã³
ãæ§çµç¹è «ã«ãããŠïŒŽãªã³ãçã®é®æç©è³ªãšããŠ
äœçšããããã«ãã€ãŠãã®ãããªçŽ°èããããžèµ€
è¡çãšèªçºçã«ããŒããã圢æããã®ãæããã
ãšãçºèŠãããã¢ããçã®ãFerritin on the
Surface of Lymphocytes in Hodgkinâ²s
Disease Patientsâïœ Possible Blocking
Substance Removed by LevamisoleãïŒClin.
Exp.Immunol.ã29ã30ïŒ1977ïŒïŒãåç §ããã
ããããã«ãã€ãŠä¹³ããã®åŸŽåãšããŠã®ããšãªã
ã³ãæ ããªã³ãçãåè¿°ã®çŽ°èå·å®³ãã¹ãã«ãã€
ãŠå®éããããšããç 究ãå°ãããã®ããç¥ããª
ãããã®çŽ°èå·å®³ãã¹ãã®èããæ¬ ç¹ã®ïŒã€ã¯æ£
è ã®çŽ°èã«äœ¿çšãããåè©Šè¬ã®å¹æãå¥ã ã«è©äŸ¡
ããªããã°ãªããªããšããããšã§ããã æ¬çºæã®ããšãªãã³ãæ ããªã³ãçã®æ€åºå®é
æ¹æ³ã¯è¿ éã§ãã€äŸµå ¥æ§ããªããæ¬çºæã®ãã¹ã
æ¹æ³ã¯ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã®æ€åºã«
å®éšçã«äœ¿çšã§ããã ãã§ãªããä¹³ããçã®ã¬ã³
ã®çºèŠããã³æ²»çå¹æãè©äŸ¡ããã®ã«äœ¿çšããã
ãšãã§ããã 次ã«æ¬çºæã«äœ¿çšãããè©Šè¬ã«ã€ããŠèª¬æã
ãã (1) æšèããæããããšãªãã³æäœ ä»¥äžã«è¿°ã¹ãå®éšã«ãããŠäœ¿çšãããããšãª
ãã³æäœã¯åç¹ç°çããããšãªãã³æäœã§ã
ããããç¹ç°æ§ã®åŒ·ãæäœãããªãã¡ã€ãœããš
ãªãã³ç¹ç°çæäœãã以äžã«è¿°ã¹ãæšèããã
ãããšãªãã³æäœã®èª¿è£œæ¹æ³ã«ãããŠæ£åžžãªã
ãããšãªãã³ã®æ¿ãã«å°ãªããšãïŒçš®ã®ã€ãœã
ãšãªãã³ããªãã¡çé»çã«æ±ºå®ãããç¯å²ã®ã€
ãœããšãªãã³ã§çœ®æããããšã«ãã€ãŠèª¿è£œãã
ããšãã§ããã æšæºçãªå ç«åŠçãªæ¹æ³ãçšããŠã©ããããš
ããããšãªãã³ã§å ç«ããã次ã®ãããªèŠªåæ§
粟補æ¹æ³ã«ãã€ãŠåç¹ç°çæäœãç£çããããš
ãã§ãããç䟡ã®æ¹æ³ã¯åœæ¥è ã«ã¯å®¹æã«åã
ãã§ãããã ç²åãµã€ãº200ã400ã¡ãã·ãŠã®ã¢ãªã«ã¢ãã³
ã®å¶åŸ¡åïŒ1350â«ïŒã¬ã©ã¹ãã°ã«ã¿ã«ã¢ã«ãã
ãïŒã¬ã©ã¹ïŒïœåœããïŒmlïŒã§æŽ»æ§åãããã
ã®ã¬ã©ã¹ãæŽã€ãŠæªåå¿ã®ã°ã«ã¿ã«ã¢ã«ããã
ãé€å»ããåŸãã¬ã©ã¹ïŒïœåœããïŒmgã®ããã
ãšãªãã³ããã®æŽ»æ§åããã¬ã©ã¹ãšå®€æž©ã§çŽïŒ
æééãã«æ··åããã次ã«1Mã®å¡©åãããªãŠ
ã ãš0.1Mã®ã°ãªã·ã³ã§ç¶ããŠæŽããããã«
0.1Mã®ãªã³é žå¡©ç·©è¡æ¶²ã§ïŒãïŒåæŽãããã®
ã¢ãªã«ã¢ãã³ã¬ã©ã¹ã¯å ¬ç¥ã®æ¹æ³ã«ãã€ãŠå®¹æ
ã«èª¿è£œããããšãã§ãããäŸãã°ãWeetallã
Scienceã166ã615ïŒ1969ïŒããåç §ããããã 次ã«ãã®ããšãªãã³ã®çµåããã¬ã©ã¹ããã®
ã¬ã©ã¹ïŒïœåœããçŽïŒmlã®ããšãªãã³æè¡æž ãš
éãã«æ··åããã22âã§äžæ©å¹é€ããåŸ0.1M
ã®çé žãããªãŠã ã0.15Mã®å¡©åãããªãŠã
ïŒPH8.0ïŒã0.1Mã®é ¢é žãããªãŠã ããã³0.15M
ã®å¡©åãããªãŠã ïŒPH5.0ïŒã§ç¶ããŠæŽããã
ãã«1Mã®å¡©é žã§PH4.4ã«èª¿ç¯ããèžçæ°Žã§ïŒåºŠ
æŽããPH2.2ã«èª¿ç¯ããèžçæ°Žã§åç¹ç°çæäœ
ã溶åºãããããã®ã¹ã©ãªãŒã0.3Mã®ãªã³é ž
ãããªãŠã å ã«éãããã®æ¶²ãéå€éã«
ãã€ãŠæ¿çž®ãããæäœã¯0.02ïŒ ã®ã¢ãžåç©ãå«
ã0.1Mãªã³é žãããªãŠã 溶液å ã«è²¯èµããã
ãšãã§ããããã®æäœã¯æŸå°æŽ»æ§æšèãé µçŽ æš
èãè¢å æšèçåŸæ¥ã®ã©ã®ãããªæšèãšãçµå
ãããããšãã§ããããããã§ã¯ãã®åç¹ç°ç
ããããšãªãã³æäœã¯NaI125ã«ãã€ãŠæŸå°æŽ»æ§
æšèããã (2) ããšãªãã³éœæ§åæ žçŽ°è ãã®è©Šè¬ã¯äžèš(1)ã®è©Šè¬ã®å®å®æ§ãã¢ãã¿ãŒ
ããæ¬çºæã®æ¹æ³ã®æå¹æ§ã確èªããããã«éœ
æ§ã®å®æ§å¯Ÿç §ãšããŠäœ¿çšãããã ãã®è©Šè¬ã調補ããã®ã«äœ¿çšãããåæ žçŽ°è
ãšããŠã¯ãèªç¶ã®ãããªã³ãçã§ã¯èµ·ããã¡ãª
ããšãªãã³ã¬ãã«ã®å€åãé¿ããããã«å¹é€å¢
æ®ãããªã³ãçã䜿çšããã®ãæ®éã§ãããã
ãã§ã¯ãæ¥æ§ãªã³ãæ¯çŽ°èæ§çœè¡ç 现è
ïŒCCLâ119ãATCCïŒã䜿çšããããããºã
ãªã³ãçïŒCCLâ86ãŸãã¯CCLâ126ã©ã€ã³ïŒ
çã®ä»ã®å¹é€ããããªã³ãçã䜿çšããããšã
ã§ãããããŸãé©åãªç¯©åããã§ããã°æ£åžžãª
å®éšææã®æ«æ¢¢è¡æ¶²ãªã³ãçã§ã䜿çšããããš
ãã§ããããã®ãããªåæ žçŽ°èã¯ããªãã¡æ«æ¢¢
è¡æ¶²åæ žã¿ã€ãã®çŽ°èã§ããããã®ãããªçŽ°è
ã¯å€©ç¶ã®æ«æ¢¢è¡æ¶²åæ žçŽ°èãšäŒŒãè¡šé¢èç¹æ§ã
瀺ãããããã°ã倩ç¶ã®æ«æ¢¢è¡æ¶²åæ žçŽ°èã§ã
ãå¿ èŠã¯ãªãã ãã®å®éšã§ã¯ããã®éœæ§å®æ§å¯Ÿç §è©Šè¬çŽ°èã¯
10ïŒ ã®çã®èå ã®è¡æž ïŒFCSãGrand Island
Biological Co.ïŒããŠãŒãšãŒã¯å·ã°ã©ã³ãã¢ã€
ã©ã³ãïŒè£œïŒã§è£è¶³ããRPMIâ1640å¹é€åº
ïŒåäžïŒå ã§å¢æ®ããæ¥æ§ãªã³ãæ¯çŽ°èæ§çœè¡
ç 现èïŒCCLâ119ïŒã䜿çšããŠèª¿è£œãããã
ã®çŽ°èã¯æ¹æå¹é€æ³ã䜿çšããé£ç¶å¹é€ã«ãã€
ãŠå¢æ®ãããããšãã§ãã倧éçç£ã«é©ããŠã
ãããã®CCLâ119ã200ã300xïœ15åéé å¿
æ²æŸ±ãããŠæ¡éãããªã³é žç·©è¡é£å¡©æ°ŽïŒPBSã
0.01Mãªã³é žå¡©ã0.15Må¡©åãããªãŠã ãPH
7.4ïŒã§ïŒåºŠæŽã€ãããã®çŽ°èãïŒãïŒÃ107
åïŒmlãšãªãããã«PBSå ã§åæ§æãããå
åãªéã®ã°ã«ã¿ã«ã¢ã«ãããã®25ïŒ ïŒïœïŒïœïŒ
溶液ãå ããŠæçµçãªã°ã«ã¿ã«ã¢ã«ãããæ¿åºŠ
ãçŽïŒïŒ ãšãªãããã«ããããã®æ¿åºŠããé«ã
å¯åºŠã§æŽ»æ§åãããšåºç¯å²ã«äºã现èåéãèµ·
ããããã®çŽ°èã22âã§30åéé£ç¶çã«ããã
ãªããå¹é€ããåŸãé å¿æ²æŸ±ã«ãã€ãŠæ¡éããŠ
æŽã€ãã粟補ããããããšãªãã³ïŒã«ãªããªã«
ãã¢å·ãµã³ã«ãŒã¹ãªãã¹ãã®JBL Chemical
Company補ïŒãPBSã§åžéãã200ã300ÎŒïœïŒ
mlã®æ¿åºŠãšãããã®çŽ°èãã¬ããã«å åå ããŠ
现èæ¿åºŠãïŒãïŒÃ107åïŒmlãšãªãããã«ã
ãã ãã®çŽ°è22âã§30åéããããªããå¹é€ãã
ããã«16ã18æéïŒâã§å¹é€ããããã®çŽ°èã
åè¿°ã®ããã«ããŠæŽããïŒïŒ ã®çã®è¡æž ã¢ã«ã
ãã³ïŒBSAïŒãš0.2ïŒ ã®ã¢ãžåãããªãŠã ãå«
ãPBSå ã«æžæ¿ããããèªå°ããã现èã®æ
åã®éå£ããå¹³åååçã¯40ã50ïŒ ã§ãã€ãã
ãã®çŽ°èãïŒâã§ä¿åãã40æ¥éã«I125ã§æšè
ããããããšãªãã³æäœã®ç¹ç°ççµåã«ãã€ãŠ
è©äŸ¡ãããšãã掻æ§ã®æžå°ã¯10ïŒ ã®ã¿ã§ãã€
ãã ã©ãããã®æããããšãªãã³è¡æž ãšããã«ãª
ã¬ã»ã€ã³ã«çµåãããå±±çŸã®æã©ãããè¡æž ã
䜿çšããŠéæ¥å ç«è¢å æ³ã«ãã€ãŠãã®çŽ°èãè©
䟡ãããšãã43ïŒ ã®çŽ°èãè¢å ã瀺ããããã
ã«å¯ŸããŠãããšãªãã³ã«çµåãããŠããªã
CCLâ119ããªãã¡çã®è¡æž ã¢ã«ããã³ã«çµå
ãããCCLâ119ã¯è¢å ã瀺ããªãã€ãããã®
éœæ§å®æ§å¯Ÿç §çŽ°èã¯æ£åžžãªã©ãããè¡æž ãšãšã
ã«å¹é€ãããšãã«ã¯è¢å ã瀺ããªãã€ãããŸã
ãã®çŽ°èäžã®ããšãªãã³ã®éã¯çŽ25ã40nïœïŒ
2.5Ã105åã§ãã€ãã (3) 粟補ããããããšãªãã³ ãã®è©Šè¬ã¯åžè²©ãããŠãããåå®éçãã¹ã
ã¢ãŒãããã³å®éçãã¹ãã¢ãŒãã®äž¡æ¹ã«äœ¿çš
ããããåå®éçã¢ãŒãã§ã¯ç¹ç°çæšèæäœçµ
åãè©äŸ¡ããããã«ãæ£è ã®ãªã³ãçäžã«ååš
ããããšãªãã³ãžã®æšèããããšãªãã³æäœã®
çµåãè©°æçã«é®æããããã«é«æ¿åºŠã§äœ¿çšã
ããããŸãå®éçã¢ãŒãã§ã¯ãªã³ãçã«çµåã
ãããšãªãã³ã®çµ¶å¯Ÿå€ã決å®ããããã®æšæºæ²
ç·ãåŸãããã«ã€ã ãã©ãžãªã¡ããªãã¯ã¢ãã»
ã€ïŒIRMAïŒãšã®é¢é£ã«ãããŠçš®ã ã®æ¿åºŠã§äœ¿
çšãããã (4) åºå®ãããããããšãªãã³æè¡æž ãã®è©Šè¬ã¯ãªã³ãçã«çµåããããšãªãã³ã®
å€ãå€æ¿æ³ã«ãã€ãŠæšå®ããããã®æšæºæ²ç·ã
åŸãããã«äžèšè©Šè¬ïŒããã³ïŒãšã®é¢é£ã«ãã
ãŠäœ¿çšãããå¶åŸ¡åã¬ã©ã¹ã®ãããªåºäœã«å ±æ
çµåããããããšãªãã³æè¡æž ãããªã€ãŠã
ãã 以äžã«è¿°ã¹ããã¹ãã§ã¯ãã®è©Šè¬ã¯ç²åãµã€
ãº1ÎŒãæ°åãµã€ãº550â«ã®ã¢ãªã«ã¢ãã³ã®å¶åŸ¡
åã¬ã©ã¹ã䜿çšããŠèª¿è£œããã ãã®ã¬ã©ã¹ããŸã2Nã®å¡©é žãšäºç¡é žãããª
ãŠã ïŒâã§æŽ»æ§åããã20ååŸã«ãã®ã¬ã©ã¹ã
èžçæ°Žã§å åæŽã€ãã次ã«ãã®ã¬ã©ã¹ïŒïœåœã
ãïŒmlã®ä¿åããããšãªãã³æè¡æž ãå ããã
PHã8.4ã«èª¿æŽããïŒâã§äžæ©åå¿ããããã
ã®åºå®ãããæäœãPH7.0ã®0.1Mãªã³é žç·©è¡æ¶²
å ã§å åæŽãã0.1ïŒ ã®BSAãå«ãPH7.0ã®
0.01Mãªã³é žç·©è¡æ¶²å ã«æçµæ¿åºŠ20mgïŒã¬ã©
ã¹ïŒïŒmlã§ïŒâã§ä¿åããã 以äžæ¬çºæã®æ¹æ³ãå®æœããããã®äžèšåè©Šè¬
ã䜿çšãããã¹ãã¢ãŒãã«ã€ããŠè©³çŽ°ã«èª¬æã
ããäžè¬ã«ãäžèšè©Šè¬ïŒãïŒãïŒïŒæšèãããã
ããšãªãã³æäœãããšãªãã³éœæ§ãªã³ãçããã³
粟補ããããããšãªãã³ïŒã¯åå®éç枬å®ãè¡ãª
ãã®ã«äœ¿çšããããŸãïŒã€ç®ã®åºå®ãããããã
ãšãªãã³æè¡æž ãå«ãå šãŠã®äžèšè©Šè¬ã¯ãªã³ãç
ã«çµåããããšãªãã³ã®å®éã«äœ¿çšãããã å®éçãã¹ããåå®éçãã¹ãã®ããããå¿ èŠ
ã§ããã«ããŠãããã¹ãæåã¯æ£è ã®æ«æ¢¢è¡æ¶²å
æ žçŽ°èãç¹ã«ãªã³ãçã®ãµã³ãã«ã§ããã泚ææ·±
ãåæããã°æ£è ã®å šãŠã®çœè¡çã®ãµã³ãã«ïŒäŸ
ãã°ççæ§çç®ïŒã䜿çšã§ãããšæãããããã
ãã§ã¯ç¬¬ïŒã®ã¹ããããšããŠæ«æ¢¢è¡æ¶²åæ žçŽ°èã®
ä»ã®è¡æ¶²æåããåé¢ããæ¹ãè¯ãããã®æ«æ¢¢è¡
液åæ žçŽ°èãšä»ã®è¡æ¶²æåãšã®åé¢ã¯å ¬ç¥ã®æ¹æ³
ã«ãã€ãŠè¡ãªãããšãã§ãããäŸãã°åæ žçŽ°èã»
ãã¬ãŒã¿ãŒã䜿çšããã°ãããã«ãŒãã©ãŒ
ïŒLudererïŒçã®ãRapidãQuantitatine Human
Lymphocyte Separation and Purification in
ïœ Closed SystemãïŒMolecular Immunol.ã
16ã621ïŒ1979ïŒãããã¯ãã€ã ïŒBoyumïŒã®
FicollâHypaqueæ³ïŒScand.J.Immunol.ãïŒïŒå¢
åïŒïŒãïŒïŒ1976ïŒïŒãåç §ãããããé å¿æ²æŸ±ç
ã®å ¬ç¥ã®æ¹æ³ã«ããæŽæµãããã³è¡çèšç®åšä¹è³
èªåè¡çã«ãŠã³ã¿ãŒã«ããèšæ°ã«ãã€ãŠçŽ°èæ°ã
èŠæ Œåããããšã§æ¬çºæã®æ¹æ³ã®æºå段éãçµäº
ãããå¿ ããå¿ èŠãªãã®ã§ã¯ãªãããæ«æ¢¢åæ žçŽ°
èã®ãªã³ãçãã©ã¯ã·ãšã³ãå ¬ç¥ã®æ¹æ³ã§åŸãŠã
ã¹ããµã³ãã«ãšããŠäœ¿çšããããšãã§ããã åå®éçã¢ãŒãã«ãããŠã¯ãåèšãªã³ãçã®äž
å®éãæšèããæããããšãªãã³æäœã®äžå®éãš
æ··åããããã®ãšãäžå®éã®ç·©è¡æ¶²ãæ··åããã®
ãæãŸãããå¥ã«ããã®æ£è ã®ãªã³ãçãæšèã
ãæããããšãªãã³æäœããã³äžå®éã®ç²Ÿè£œãã
ããããšãªãã³ïŒããã¯ç·©è¡æ¶²ã®æ¿ãã«ããªããïŒ
æ··åããŠéåžžã®è©°æçãã¹ãçµååç §ãšãããã
ãã¯ããããšãªãã³ãæšèããæäœã®ãã¹ã现è
ãžã®ã©ã®ãããªç¹ç°ççµåãè©°æçã«ãã¬ããã
èšæ°ãããç¹ç°ççµåãšããŠå ±åãããåå®éã®
çµæã¯ããå ããéå°ã®ããããšãªãã³ãã®éå
åšäžã§ã®cpmïŒïŒåéåœãã®èšæ°ïŒçµåãã枬å®
ç³»ã«å ããããI125ã§æšèããæäœã®ç·éã®cpm
ããå ããããéå°ã®ããããšãªãã³ã®ååšäžã§
ã®çŽ°èãžã®cpmçµåãåŒãããã®ã§å²ã€ãå€ãã
éå°ã®å¯æº¶æ§ããããšãªãã³ã®ååšäžã§ã®çŽ°èãž
ã®cpmïŒïŒåéåœãã®èšæ°ïŒçµåãåŒãããšã«ã
ã€ãŠæ±ºå®ãããããã®ãå ããããéå°ã®ããã
ãšãªãã³ããšã¯æšèããæäœã®çŽ°èãžã®ç¹ç°ççµ
åãå®å šã«é®æããããã«æž¬å®ç³»ã«å ããããå¯
溶æ§ããšãªãã³ã®ç·éãšããŠå®çŸ©ãããã äžè¬ã«ãç¹ç°ççµåã¯å°ãªããšãïŒã€ã®ç°ãªã
现èæ¿åºŠã§è©äŸ¡ããããçµæã¯ç¹å®çŽ°èæ°åœãã®
æ«æ¢¢è¡æ¶²ãªã³ãçãžã®cpmãããã¯çµåçã§å ±å
ããããé®æãããããªé«æ¿åºŠã§å ãããããã
ã§ããã第ïŒæ®µéã¯ïŒç¬¬ïŒæ®µéãšãã€ãŠãŠããã¡
ããäžèšãã¹ãã®åã§ãåŸã§ããŸãåæã«ã§ãå·®
ãæ¯ããªããïŒäžèšïŒã€ã®æäœããã¹ã现èã®æ¿
ãã«ããšãªãã³éœæ§ãªã³ãçã䜿çšããŠè¡ãªãã
枬å®ç³»ã®æ©èœæ§ãšæšèããæäœã®å®å®æ§ãã¢ãã¿
ãŒããããšã§ããããã以äžã®ããšãã¯ãå¿ èŠã§
ããå Žåã«ã¯ä»»æã®ã¹ããããšããŠãããšãªãã³
éœæ§ãªã³ãçã®æ¿ãã«å¯Ÿç §é°æ§çŽ°èã䜿çšããŠç¬¬
ïŒæ®µéãšåãæäœãããŠãããããã®å¯Ÿç §é°æ§çŽ°
èãšããŠã¯çã®è¡æž ã¢ã«ããã³ãæ ãCCLâ119
ãªã³ãçã®ãããªãæšèããæäœãšåå¿ããªãè
çœãæ ããã®ã䜿çšããã é©åœãªå¹é€æéã®åŸãåèšçŽ°èãæŽã€ãŠé å¿å
é¢ãããäžæŸãååããŠãã¬ããåãã现èã®çµ
åæšèãè©äŸ¡ãããI125ã§æšèããæäœã䜿çšã
ãå Žåã«ã¯Î³ç·ã¹ãã¯ããã¡ãŒã¿ãŒå ã§å®éç枬
å®ã«ãããŠã¯æ£è ã®ãªã³ãçãšå®æ§å¯Ÿç §ãªã³ãç
ã®æž¬å®ãäžè¿°ãšåæ§ã«ããŠè¡ãªããããã«ããã
ãšãªãã³ãéãå¢ããªããäžå®æ¿åºŠã®åºå®ããã
æããããšãªãã³æè¡æž ïŒIMAïŒãšãšãã«å¹é€
ããŠæšæºæ²ç·ãäœæããããã®ç³»ã§ã¯IMAããŸ
ãç·©è¡æ¶²ã®ã¿ãšæ··åãããããããã¯çš®ã ã®æ¿åºŠ
ã®ããããšãªãã³ãšæ··åããããã¹ã现èãåæ
ããã®ã«äœ¿çšããã®ãšåãæçµçãªæéééãŸã§
äžå®æéééã§æšèããæäœãå ããŠå¹é€ãç¶ã
ãããã®IMAãç·©è¡æ¶²ã§æŽã€ãŠãé å¿æ²æŸ±ã«ã
ã€ãŠãã¬ããåãããäžæŸããã«ã³ãããŠããã¬
ããã®æŸå°ç·æŽ»æ§ãè©äŸ¡ãããåããããšãªãã³
æ¿åºŠã«ã€ããŠç¹ç°ççµåããç·©è¡æ¶²ã®ã¿ãååšã
ããšãã®IMAãžã®cpmçµåãã次第ã«éãå¢ã
ããå ããããããšãªãã³ãã«ãããå ããæäœ
ã®ç·cpmãšcpmçµåã®äž¡æ¹ããåŒã以å€ã¯äžèšãš
åæ§ã«ããŠæ±ºå®ãããç察æ°æ¹çŒçŽã®çŽç·ç®çã«
ç¹ç°ççµåããšãã察æ°ç®çã«å ããããšãªãã³
ã®éããšã€ãŠããããããŠæšæºæ²ç·ãäœæããã
æ£è ã®çŽ°èã«ããç¹ç°ççµåã察æ°ç®çã«å€æ¿ã
ãããšã«ãã€ãŠæ£è ã®æ«æ¢¢è¡æ¶²ãªã³ãçã«çµåã
ãããšãªãã³ã®å®éããªããããä»ã®ãšããã§
ã¯ããã®æšæºæ²ç·ã¯æ£è ã®ãã¹ãã«äœ¿çšããã®ãš
åãããããšãªãã³ã䜿çšããŠæ£è ã®ãã¹ãã®éœ
床äœæããæ¹ãè¯ããšæããããèŠæ Œåãšè²¯èµå¯¿
åœããªãã¡å®å®æ§ãæ¹è¯ãããã°ãæšæºæ²ç·ã®äœ
æã¯ãããªã«é »ç¹ã«è¡ãªããªããŠãããªãã§ãã
ãããã¡ãããã¢ã€ãœããŒãã䜿çšããå Žåã«ã¯
ãã®éœåºŠæšæºæ²ç·ãäœæããªããã°ãªããªãã ãã¡ããäžèšåã¢ãŒãã«ãããŠãè©Šè¬ãšãã¹ã
çµæã確èªããããããšãªãã³éœæ§ãªã³ãçã䜿
çšããåèšç¬¬ïŒæ®µéã®æž¬å®ã§åŸãããçµæã䜿çš
ããŠåãèšç®ããªãããã åŸã«è©³çŽ°ã«èª¬æããããã«ãããã§èª¬æããã
ã¹ãæ¹æ³ã¯ã¬ã³ã®æ©æçºèŠããã³æ²»çå¹æãã¢ã
ã¿ãŒããæå¹ãªæ段ãšããŠäœ¿çšããããšãã§ã
ããæ£åžžãªå¥åº·äººã®å Žåã«ã¯ã粟補ããããããš
ãªãã³ãååšããå Žåãšååšããªãå Žåã®çµåæš
èã®æž¬å®å€ã«ã¯æ®ã©å·®ããªããããã€ãŠãå°ãã
ããåæã®ïŒç å以åã®ïŒã¬ã³ãããã¯é²è¡ãã
ã¬ã³ã®æ£è ã®æ«æ¢¢è¡æ¶²ãªã³ãçã®å Žåã«ã¯ããã
ãšãªãã³ãååšããªãç³»å ã®çµåæšèãå¢å ã
ãã 次ã«ãåè¿°ããè©Šè¬ã䜿çšãã枬å®æ¹æ³ãäŸã
æããŠæŽã«è©³çŽ°ã«èª¬æããã åè¡ãææ¢ãããè¡æ¶²èŠæ¬ããåè¿°ã®ãã€ã ã®
æ¹æ³ã«ãã€ãŠãªã³ãçãåé¢ããããã®ãšããªã³
é žå¡©ã§ç·©è¡ããçççé£å¡©æ°Žã§ãã®èŠæ¬ãïŒïŒïŒ
ã§åžéãããã®è¡æ¶²ããã€ã³ã«âãã€ããã¯
ïŒFicollâHypaqueïŒæº¶æ¶²äžã«å±€ããªãããã«é
ãã«æ³šãã ã次ã«400Ãïœã§30åéé å¿æ²æŸ±ãã
ããšãããªã³ãçãæ確ãªçé¢ãæã€ãŠåž¯ç¶ããª
ãããããããã¹ããŒã«ããããã§åãåºããç·©
ãããªé å¿æ²æŸ±ïŒ200Ãïœã10åéïŒã«ãã€ãŠ
PBSå ã§ïŒåºŠæŽã€ããããã«ããããïŒÃ107
åïŒmlã®æ¿åºŠã§0.1ïŒ ã®BSAãš0.02ïŒ ã®ã¢ãžåã
ããªãŠã ãå«ãPBSä¹è³RPMIå¹é€åºå ã«æžæ¿ã
ãããå¯Ÿç §éœæ§çŽ°èïŒããšãªãã³ãæ ããªã³ã
çïŒããã®æ¿åºŠã§æžæ¿ãããã å现èæ¿åºŠã«ãããŠãã¹ãããåèŠæ¬ã«ïŒæ¬ã®
12Ã75mmã®ãã©ã¹ããã¯è©Šéšç®¡ãå²ãåœãŠããïŒ
âã®æ°ŽæµŽã®äžã§åå¿ãéå§ããããåè©Šéšç®¡ã«
100ÎŒã®çŽ°èãå ãããåçµã®æåã®ïŒæ¬ã®è©Š
éšç®¡ã«ã¯ããã«100ÎŒã®PBSâBSAâã¢ãžåç©
溶液ãå ããæ®ãã®ïŒæ¬ã®è©Šéšç®¡ã«ã¯10ã50ÎŒ
ïœïŒmlã®æ¿åºŠã§ïŒéå°ã®HFïŒPBSâBSAâã¢ãž
åç©æº¶æ¶²ã«å ããããããããšãªãã³100ÎŒã
泚ãã ããã®æ¿åºŠã¯ïŒÃ106åã®éœæ§å¯Ÿç §çŽ°èãž
ã®I125æšèã®æäœã®ç¹ç°ççµåãé®æããã®ã«å
åã§ãã€ãã100ÎŒã®I125æšèæäœïŒ50000ã
100000opmïŒãå ããåŸããã®è©Šéšç®¡ãã·ãšãŒã«
ãŒæµŽã«ç§»ããŠïŒâã§äžæ©ïŒ16ã18æéïŒå¹é€ããŠ
çµåã平衡ã«éãããããå¹é€ã®åŸãïŒmlã®
PBSã§çŽ°èãæŽãã3000rpmã§15åéé å¿æ²æŸ±ã
ãããäžæŸãã¢ã¹ãã¬ãŒãããŠã现èãã¬ããã®
çµåæŸå°æŽ»æ§ãèšæ°ããããã®ããã«ããŠåŸãç¹
ç°ççµåã®å埩詊éšã«ãã€ãŠåŸãå€ãå¹³åããã ããããšãªãã³ã®ã»ãŒå®å šãªçµåé®æäœçšã«ã
ã€ãŠãã¹ã现èã«çµåããããšãªãã³ã«å¯Ÿããæš
èããšãªãã³æäœã®ç¹ç°æ§ã確ç«ããããšãšã
ã«ã现èè¡šé¢ãžã®éç¹ç°çåžçãäœã¬ãã«ã«ä¿ã
ããã 次ã«æ¬çºæã®æž¬å®æ¹æ³ã®æ¥µããŠé«ãæ床ã«ã€ã
ãŠèª¬æããã ãªã³ãçäžã®ããšãªãã³ã枬å®ãåŸãæ床ã®äž
éãããããšãªãã³ã®æ¿åºŠãå¢ããªãããäžå®æ¿
床ã®æŸå°ç·æšèããããšãªãã³æäœãš2.5Ã105ã®
éœæ§å¯Ÿç §çŽ°èïŒæ確ãªéã®ããšãªãã³ãæ ã€ã
CCLâ119ïŒã䜿çšããŠè©°æçµåã«ãã€ãŠæ±ºå®ã
ããæ€åºã®äžéã¯ïŒã2.5Ã19-9ïœããããã¯4.4
ã5.5Ã10-6ããã¢ã«ã§ããããšãåãã€ããã
ã®äžéã¯æŸå°ç·æšèããããšãªãã³æäœã®éœæ§å¯Ÿ
ç §çŽ°èãžã®ç¹ç°ççµåãåçŸå¯èœã«çŠæ¢ãåŸãã
ãããšãªãã³ã®æå°éã«åºã¥ããã®ã§ããã é°æ§çŽ°èã®éå£å ã®ããšãªãã³ãæ ã现èã®æ€
åºå¯èœãªæå°ã®æ°ãæçµçŽ°èæ°2.5Ã105åãšãªã
ããã«é°æ§çŽ°èãšæ··åããå¯Ÿç §éœæ§çŽ°èã䜿çšã
ãŠç 究ããããã®çŽ°èå¯åºŠã«ãããŠã12500åã®
现èãïŒïŒ ç¹ç°ççµåã®èå¥ã¬ãã«ã§æ€åºããã
ãšãã§ãããåèšå®éããŒã¿ããèŠããšãããã¯
æ€åºã®äžéã§ããããšãªãã³ã®çµ¶å¯Ÿå€çŽ2nïœã«
察å¿ããŠããããããã€ãŠçŽ°èæ°ïŒÃ106ã®éå£
ã®å Žåã«ã¯1.25ïŒ ã®éœæ§çŽ°èãæ€åºãåŸããšèã
ããããæç®ã«ããã°ãªã³ãçã®ç·æ°ã®ãã¡16.6
ïŒ ãããšãªãã³éœæ§çŽ°èã§ãããšãããšä¹³ããã®
城åããããšãããŠããããïŒã¢ããçã®
ãCancer Immunol.Immunother.ããïŒã101
ïŒ1977ïŒïŒããã¯æ¥µããŠçŽ æŽãããå€ã§ããã 次ã«å®éçãªæž¬å®ã«ãããŠæšæºæ²ç·ãäœæãã
äžè¬çãªæ¹æ³ã説æããã è€æ°ã®å šãåã12Ã75mmã®è©Šéšç®¡ã«ä¿åIMA
ïŒã¬ã©ã¹20mgïŒmlïŒããåãåºããŠPBSâBSAâ
ã¢ãžåç©æº¶æ¶²ã§äºãïŒïŒ10ã§åžéããããããšãª
ãã³æè¡æž IMA100ÎŒãå ãããåã»ããã®è©Š
éšç®¡ã«100ÎŒã®ç·©è¡æ¶²ãåç¬ã§å ãããããã
ããšãªãã³ãç·©è¡æ¶²ã§çš®ã ã®éã«åžéãããã®ã
å ããããã®æž¬å®ã¯ïŒâã®æ°ŽæµŽå ã§éå§ããã次
ã«ãã®è©Šéšç®¡ãã·ãšãŒã«ãŒæµŽå ã§30åé22âã«ä¿
ã€ããã®æéã®çµãã«æŸå°ç·æšèããããšãªãã³
æäœïŒ100ÎŒïŒIMAãå ¥ã€ãåè©Šéšç®¡ã«å ãã
æŽã«30åéä¿æž©ãç¶ããããã®è©Šéšç®¡ãéœæ§å¯Ÿç §
èŠæ¬ãšåãæ¹æ³ã§æŽã€ãŠé å¿æ²æŸ±ããããå¯Ÿç §èŠ
æ¬ã®å Žåãšã¯ç°ãªããæŸå°ç·æšèããæäœã¯æž¬å®
ã®éå§æã«ã¯å ãã30ååŸã«å ãããããã«ãã€
ãŠæšèããæè¡æž ãå ããåã«ããããšãªãã³ã
IMAæè¡æž ãšå¹³è¡¡ã«éããããšãã§ããããã
ããªããå¹é€æéãé©åœã§ããã°æšèããæäœã
åæã«å ããããšãã§ããã çš®ã ã®æ¿åºŠã«åžéããéœæ§å¯Ÿç §çŽ°èã«å¯Ÿããç¹
ç°ççµåãæšæºæ²ç·ããå€æ¿ããããšã«ãã€ãŠã
ãšãªãã³çµåã®çµ¶å¯Ÿéã決å®ããããšãã§ããã 第ïŒè¡šã¯æ¬çºæã®åå®éã¢ãŒãã®æž¬å®æ¹æ³ã«ã
ã€ãŠå€æ°ã®æ£è ããã¹ãããçµæã瀺ããã®ã§ã
ããæ£ç¢ºåºŠããã³æ£è ã®çš®é¡ã¯ä»ã®èšºææ¹æ³äŸã
ã°çäœçµç¹æ€æ»ã«ãã€ãŠæ±ºå®ããã
ãè¡šã
第ïŒè¡šããæãããªããã«æ¬çºæã®ãã¹ãã¯é
æªæ§ã®æ£è ãèŠåãããŸãæ²»çå¹æãèŠãã®ã«é©
ããŠããã 第ïŒè¡šã¯æŸå°ç·æšèïŒI125ïŒããæããããšãª
ãã³æäœã䜿çšãïŒâã§16ã18æéå¹é€ããŠåå®
éãã¹ããè¡ãªã€ããšãã®ããšãªãã³éœæ§ãªã³ã
çã®å®éçãªå¹³åå€ã瀺ããã®ã§ããããã®ç¬¬ïŒ
è¡šã®å€ã¯å°æ°ã®æ£è ã«åºã¥ããã®ã§ã¯ãããæªæ§
ã®ç¶æ ãšéæªæ§ã®ç¶æ ã®éã®çžå¯Ÿå€ã瀺ããŠã
ãã 第ïŒè¡š ïŒ æ£åžžãªå¥³æ§ã«ãããçµåã¯0.4ã4.5ïŒ ã®ç¯å²
ã«ãããå¹³åïŒïŒ ã§ãã€ããããã«å¯ŸããŠ50æ
ãè¶ ãã女æ§ã®å Žåã¯ãã®å€ã倧ããã€ãã ïŒ ä¹³æŒçãç¹ç¶è «çãç¹ç¶è ºè «ãå«ãè¯æ§ä¹³ã¬
ã³æ£è ã®å Žåã¯å¹³å1.6ïŒ ã§ãã€ãããã®å€ã¯
å åæ£åžžãªç¯å²ã«ããã ïŒ ä¹³æ¿åé€è¡ãåãåçºã®åŸŽã®ãªã女æ§ãŸãã¯
æŸå°ç·çæ³ããã³ååŠçæ³ãåããŠãã女æ§ã®
å Žåã¯æ²»çãåããŠããªã転移æ§ã®å¥³æ§æ£è
ïŒå¹³åïŒïŒ ïŒã«æ¯ã¹ãŠçµåãæžå°ããïŒå¹³å2.5
ïŒ ïŒã ïŒ ä¹³ã¬ã³ã®æè¡ãåããåã®å¥³æ§ã®å Žåã¯çµå
ã¬ãã«ãé«ãã€ãïŒ6.5ã10ïŒ ïŒã ãªããåœæ¥è ã«ã¯æãããªããã«æ¬çºæã«ã¯
çš®ã ã®ããªãšãŒã·ãšã³ããããäŸãã°ã°ã«ã¿ã«ã¢
ã«ãããã®æ¿ãã«ã·ã¢ãããããžã€ãœã·ãªã·ã¢ã
ãŒãçã®çš®ã ã®ã«ãããªã³ã°å€ã䜿çšããããšã
ã§ããããã¬ã©ã¹ã®æ¿ãã«æŸ±ç²ãã²ã«ããŒãºçã®
ä»ã®éåæå¶åºäœã䜿çšããããšãã§ããããäž
èšä»¥å€ã®æšæºæ²ç·äœææ¹æ³ã䜿çšã§ãããããŸã
ããšãªãã³ã®æ¿ãã«ãã¢ã«ãã¢èå èçœãã¬ã³è
æåã絚æ¯èæ§çæ®è ºåºæ¿ãã«ã¢ã³ãããèçµå
æåïŒpancreatic associated antigenïŒãããšã
ãµã«ããªã°ãªã³ãããã€ã³
ïŒfetosulfoglycoproteinïŒçã察å¿ããé©åœãªæ
äœãšãšãã«äœ¿çšããããšãã§ããã
æªæ§ã®æ£è ãèŠåãããŸãæ²»çå¹æãèŠãã®ã«é©
ããŠããã 第ïŒè¡šã¯æŸå°ç·æšèïŒI125ïŒããæããããšãª
ãã³æäœã䜿çšãïŒâã§16ã18æéå¹é€ããŠåå®
éãã¹ããè¡ãªã€ããšãã®ããšãªãã³éœæ§ãªã³ã
çã®å®éçãªå¹³åå€ã瀺ããã®ã§ããããã®ç¬¬ïŒ
è¡šã®å€ã¯å°æ°ã®æ£è ã«åºã¥ããã®ã§ã¯ãããæªæ§
ã®ç¶æ ãšéæªæ§ã®ç¶æ ã®éã®çžå¯Ÿå€ã瀺ããŠã
ãã 第ïŒè¡š ïŒ æ£åžžãªå¥³æ§ã«ãããçµåã¯0.4ã4.5ïŒ ã®ç¯å²
ã«ãããå¹³åïŒïŒ ã§ãã€ããããã«å¯ŸããŠ50æ
ãè¶ ãã女æ§ã®å Žåã¯ãã®å€ã倧ããã€ãã ïŒ ä¹³æŒçãç¹ç¶è «çãç¹ç¶è ºè «ãå«ãè¯æ§ä¹³ã¬
ã³æ£è ã®å Žåã¯å¹³å1.6ïŒ ã§ãã€ãããã®å€ã¯
å åæ£åžžãªç¯å²ã«ããã ïŒ ä¹³æ¿åé€è¡ãåãåçºã®åŸŽã®ãªã女æ§ãŸãã¯
æŸå°ç·çæ³ããã³ååŠçæ³ãåããŠãã女æ§ã®
å Žåã¯æ²»çãåããŠããªã転移æ§ã®å¥³æ§æ£è
ïŒå¹³åïŒïŒ ïŒã«æ¯ã¹ãŠçµåãæžå°ããïŒå¹³å2.5
ïŒ ïŒã ïŒ ä¹³ã¬ã³ã®æè¡ãåããåã®å¥³æ§ã®å Žåã¯çµå
ã¬ãã«ãé«ãã€ãïŒ6.5ã10ïŒ ïŒã ãªããåœæ¥è ã«ã¯æãããªããã«æ¬çºæã«ã¯
çš®ã ã®ããªãšãŒã·ãšã³ããããäŸãã°ã°ã«ã¿ã«ã¢
ã«ãããã®æ¿ãã«ã·ã¢ãããããžã€ãœã·ãªã·ã¢ã
ãŒãçã®çš®ã ã®ã«ãããªã³ã°å€ã䜿çšããããšã
ã§ããããã¬ã©ã¹ã®æ¿ãã«æŸ±ç²ãã²ã«ããŒãºçã®
ä»ã®éåæå¶åºäœã䜿çšããããšãã§ããããäž
èšä»¥å€ã®æšæºæ²ç·äœææ¹æ³ã䜿çšã§ãããããŸã
ããšãªãã³ã®æ¿ãã«ãã¢ã«ãã¢èå èçœãã¬ã³è
æåã絚æ¯èæ§çæ®è ºåºæ¿ãã«ã¢ã³ãããèçµå
æåïŒpancreatic associated antigenïŒãããšã
ãµã«ããªã°ãªã³ãããã€ã³
ïŒfetosulfoglycoproteinïŒçã察å¿ããé©åœãªæ
äœãšãšãã«äœ¿çšããããšãã§ããã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ æ«æ¢¢è¡æ¶²åæ žçŽ°èäžã®ãªã³ã³ãã€ãŒã¿ã«ã¢ã³
ãã€ãžãšã³ãæ€åºããæ¹æ³ã«ãããŠã çœè¡çãµã³ãã«å ã«å«ãŸããæ«æ¢¢è¡æ¶²åæ žçŽ°è
ã®äžå®éãåèšã¢ã³ãã€ãžãšã³ã«å¯Ÿããæšèãã
ãªã³ã³ãã€ãŒã¿ã«æäœã®äžå®éãšæ··åããåèšçŽ°
èã«ä»çããªãã€ãåèšæäœãé€å»ããåèšçŽ°è
ã«ä»çããåèšæäœã®çžå¯Ÿéãåèšæšèã䜿çšã
ãŠæ±ºå®ãã第ïŒã®ãã¹ããè¡ãªãå·¥çšã åèšæ«æ¢¢è¡æ¶²åæ žçŽ°èã®ä»ã®äžå®éãæšèãã
ãããªã³ã³ãã€ãŒã¿ã«æäœã®äžå®éããã³è©°æç
ã«çµåãçŠæ¢ããéã®åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³
ãã€ãžãšã³ãšæ··åããåèšçŽ°èã«ä»çããªãã€ã
åèšæäœãé€å»ãããã®çŽ°èã«ä»çããåèšæäœ
ã®çžå¯Ÿéãåèšæšèã䜿çšããŠæ±ºå®ãã第ïŒã®ã
ã¹ããè¡ãªãå·¥çšã åèšç¬¬ïŒã第ïŒã®ãã¹ãã«ãã€ãŠåŸãããå€ã
ãåèšçŽ°èã«ãã€ãŠæ ãããŠããåèšã¢ã³ãã€ãž
ãšã³ã®çžå¯Ÿéã決å®ããçžå¯Ÿé決å®å·¥çšã åèšæ«æ¢¢è¡æ¶²åæ žçŽ°èã®æ¿ãã«æ¢ç¥ã®éã®åèš
ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãæ ãæ«æ¢¢è¡æ¶²
åæ žã¿ã€ãã®çŽ°èã䜿çšããŠåèšç¬¬ïŒã第ïŒã®ã
ã¹ãã®å·¥çšããã³çžå¯Ÿé決å®å·¥çšãè¡ãªãåç §å·¥
çšãããã³ åèšåç §å·¥çšã®çµæããæ¹æ³ã®åŠ¥åœæ§ããã³å
èšæšèããæäœè©Šè¬ã®æå¹æ§ãããšãã¯ããããš
ãã¯å·¥çšã ãããªãããšãç¹åŸŽãšããæ¹æ³ã ïŒ åèšæ«æ¢¢è¡æ¶²åæ žçŽ°èãåèšçœè¡çãµã³ãã«
ããåé¢ããŠäœ¿çšããããšãç¹åŸŽãšããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãã¢ã«
ãã¢èå èçœè³ªãããšãªãã³ãã¬ã³èæåããã
絚æ¯èæ§çæ®è ºåºæ¿ãã«ã¢ã³ãããèçµåæåã
ããã³ããšããµã«ããªã°ãªã³ãããã€ã³ãããªã
矀ããéžæãããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãããš
ãªãã³ã§ããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬
ïŒé èšèŒã®æ¹æ³ã ïŒ åèšæšèãæŸå°æŽ»æ§æšèãé µçŽ æšèããã³è¢
å æšèãããªã矀ããéžæãããããšãç¹åŸŽãšã
ãç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ åèšæ«æ¢¢è¡æ¶²åæ žçŽ°èããªã³ãçã§ãããã
ã®ãªã³ãçãåèšçœè¡çãµã³ãã«ããåé¢ããŠäœ¿
çšããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èš
èŒã®æ¹æ³ã ïŒ æ«æ¢¢è¡æ¶²åæ žçŽ°èäžã®ãªã³ã³ãã€ãŒã¿ã«ã¢ã³
ãã€ãžãšã³ãå®éããæ¹æ³ã«ãããŠã çœè¡çãµã³ãã«å ã«å«ãŸããæ«æ¢¢è¡æ¶²åæ žçŽ°è
ã®äžå®éãåèšã¢ã³ãã€ãžãšã³ã«å¯Ÿããæšèãã
ãªã³ã³ãã€ãŒã¿ã«æäœã®äžå®éãšæ··åããåèšçŽ°
èã«ä»çããªãã€ãåèšæäœãé€å»ããåèšçŽ°è
ã«ä»çããåèšæäœã®çžå¯Ÿéãåèšæšèã䜿çšã
ãŠæ±ºå®ãã第ïŒã®ãã¹ããè¡ãªãå·¥çšã åèšæ«æ¢¢è¡æ¶²åæ žçŽ°èã®ä»ã®äžå®éãæšèãã
ãããªã³ã³ãã€ãŒã¿ã«æäœã®äžå®éããã³è©°æç
ã«çµåãçŠæ¢ããéã®åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³
ãã€ãžãšã³ãšæ··åããåèšçŽ°èã«ä»çããªãã€ã
åèšæäœãé€å»ãããã®çŽ°èã«ä»çããåèšæäœ
ã®çžå¯Ÿéãåèšæšèã䜿çšããŠæ±ºå®ãã第ïŒã®ã
ã¹ããè¡ãªãå·¥çšã åèšç¬¬ïŒã第ïŒã®ãã¹ãã«ãã€ãŠåŸãããå€ã
ãåèšçŽ°èã«ãã€ãŠæ ãããŠããåèšã¢ã³ãã€ãž
ãšã³ã®çžå¯Ÿéã決å®ããçžå¯Ÿé決å®å·¥çšã åèšæ«æ¢¢è¡æ¶²åæ žçŽ°èã®æ¿ãã«æ¢ç¥ã®éã®åèš
ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãæ ãæ«æ¢¢è¡æ¶²
åæ žã¿ã€ãã®çŽ°èã䜿çšããŠåèšç¬¬ïŒã第ïŒã®ã
ã¹ãã®å·¥çšããã³çžå¯Ÿé決å®å·¥çšãè¡ãªãåç §å·¥
çšã åèšåç §å·¥çšã®çµæããæ¹æ³ã®åŠ¥åœæ§ããã³å
èšæšèããæäœè©Šè¬ã®æå¹æ§ãããšãã¯ããããš
ãã¯å·¥çšã åèšã¢ã³ãã€ãžãšã³ãæå®ã®éã®åºå®ãããæ
äœããã³æå®ã®éã®æšèããæäœãšãéã次第ã«
å¢ãããªããæ··åããæšæºæ²ç·ãäœæããæšæºæ²
ç·äœæå·¥çšã åèšæšèã䜿çšããŠåã¢ã³ãã€ãžãšã³æ¿åºŠã«ã
ããç¹ç°ççµåã決å®ããå·¥çšãããã³ åèšçžå¯Ÿé決å®å·¥çšã«ãã€ãŠåŸãããå€ãåèš
æšæºæ²ç·ãšæ¯èŒããŠãã®å€ã«å¯Ÿå¿ããã¢ã³ãã€ãž
ãšã³ã®éã決å®ããå·¥çšã ãããªãããšãç¹åŸŽãšããæ¹æ³ã ïŒ åèšæ«æ¢¢è¡æ¶²åæ žçŽ°èãåèšçœè¡çãµã³ãã«
ããåé¢ããŠäœ¿çšããããšãç¹åŸŽãšããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒ åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãã¢ã«
ãã¢èå èçœè³ªãããšãªãã³ãã¬ã³èæåããã
絚æ¯èæ§çæ®è ºåºæ¿ãã«ã¢ã³ãããèçµåæåã
ããã³ããšããµã«ããªã°ãªã³ãããã€ã³ãããªã
矀ããéžæãããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯
å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒïŒ åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãã
ãšãªãã³ã§ããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²
第ïŒé èšèŒã®æ¹æ³ã ïŒïŒ åèšæšèãæŸå°æŽ»æ§æšèãé µçŽ æšèããã³
è¢å æšèãããªã矀ããéžæãããããšãç¹åŸŽãš
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®æ¹æ³ã ïŒïŒ åèšæ«æ¢¢è¡æ¶²åæ žçŽ°èããªã³ãçã§ããã
ãã®ãªã³ãçãåèšçœè¡çãµã³ãã«ããåé¢ããŠ
䜿çšããããšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
èšèŒã®æ¹æ³ã ïŒïŒ æ«æ¢¢è¡æ¶²åæ žçŽ°èäžã®ãªã³ã³ãã€ãŒã¿ã«ã¢
ã³ãã€ãžãšã³ãæ€åºããã®ã«äœ¿çšããè£ çœ®ã«ãã
ãŠã åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã«å¯Ÿãã
æšèãããããªã³ã³ãã€ãŒã¿ã«æäœãããªã第ïŒ
ã®è©Šè¬ã åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãããªã
第ïŒã®è©Šè¬ãããã³ æ¢ç¥ã®éã®åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãš
ã³ãæ ãæ«æ¢¢è¡æ¶²åæ žã¿ã€ãã®çŽ°èãããªã第ïŒ
ã®è©Šè¬ã ãå¥ã ã®è©Šè¬ãšããŠåããŠãããçœè¡çãµã³ãã«
ã®äžå®éãåèšç¬¬ïŒã®è©Šè¬ãšæ··åããã該çœè¡ç
ãµã³ãã«ã®ä»ã®äžå®éãåèšç¬¬ïŒããã³ç¬¬ïŒã®è©Š
è¬ãšæ··åãããåèšç¬¬ïŒã®è©Šè¬ã®äžå®éãåèšç¬¬
ïŒã®è©Šè¬ãšæ··åãããåèšç¬¬ïŒã®è©Šè¬ã®ä»ã®äžå®
éãåèšç¬¬ïŒããã³ç¬¬ïŒã®è©Šè¬ãšæ··åããã次ã
ã§ãåèšçœè¡çãµã³ãã«äžã®æ«æ¢¢è¡æ¶²åæ žçŽ°èã«
ããæ ãããŠããåèšã¢ã³ãã€ãžãšã³ã®çžå¯Ÿéã
決å®ã§ããããã«ãªã€ãŠããããšãç¹åŸŽãšããè£
眮ã ïŒïŒ åèšæšèãæŸå°æŽ»æ§æšèãé µçŽ æšèããã
ã³è¢å æšèãããªã矀ããéžæãããããšãç¹åŸŽ
ãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®è£ 眮ã ïŒïŒ åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãã¢
ã«ãã¢èå èçœè³ªãããšãªãã³ãã¬ã³èæåãã
ã絚æ¯èæ§çæ®è ºåºæ¿ãã«ã¢ã³ãããèçµåæ
åãããã³ããšããµã«ããªã°ãªã³ãããã€ã³ãã
ãªã矀ããéžæãããããšãç¹åŸŽãšããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®è£ 眮ã ïŒïŒ åèšæ«æ¢¢è¡æ¶²åæ žã¿ã€ãã®çŽ°èãåèšã¢ã³
ãã€ãžãšã³ãæ ãå¹é€ããããªã³ãçã§ããããš
ãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®è£
眮ã ïŒïŒ åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãã
ãšãªãã³ã§ãããåèšæ«æ¢¢è¡æ¶²åæ žã¿ã€ãã®çŽ°è
ãããšãªãã³ãæ ãå¹é€ããããªã³ãçã§ããã
ãšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®è£
眮ã ïŒïŒ æ«æ¢¢è¡æ¶²åæ žçŽ°èäžã®ãªã³ã³ãã€ãŒã¿ã«ã¢
ã³ãã€ãžãšã³ãæ€åºããã®ã«äœ¿çšããè£ çœ®ã«ãã
ãŠã åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ã«å¯Ÿãã
æšèãããããªã³ã³ãã€ãŒã¿ã«æäœãããªã第ïŒ
ã®è©Šè¬ã åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãããªã
第ïŒã®è©Šè¬ãããã³ æ¢ç¥ã®éã®åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãš
ã³ãæ ãæ«æ¢¢è¡æ¶²åæ žã¿ã€ãã®çŽ°èãããã³ åºäœäžã«åºå®ãããåèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³
ãã€ãžãšã³ã«å¯Ÿãããããªã³ã³ãã€ãŒã¿ã«æäœã
ããªã第ïŒã®è©Šè¬ã ãå¥ã ã®è©Šè¬ãšããŠåããŠãããçœè¡çãµã³ãã«
ã®äžå®éãåèšç¬¬ïŒã®è©Šè¬ãšæ··åããã該çœè¡ç
ãµã³ãã«ã®ä»ã®äžå®éãåèšç¬¬ïŒããã³ç¬¬ïŒã®è©Š
è¬ãšæ··åãããåèšç¬¬ïŒã®è©Šè¬ã®äžå®éãåèšç¬¬
ïŒã®è©Šè¬ãšæ··åãããåèšç¬¬ïŒã®è©Šè¬ã®ä»ã®äžå®
éãåèšç¬¬ïŒããã³ç¬¬ïŒã®è©Šè¬ãšæ··åããã次ã
ã§ãåèšçœè¡çãµã³ãã«äžã®æ«æ¢¢è¡æ¶²åæ žçŽ°èã«
ããæ ãããŠããåèšã¢ã³ãã€ãžãšã³ã®çžå¯Ÿéã
決å®ãããåèšç¬¬ïŒã®è©Šè¬ãå¢å ãããªããæå®
éã®åèšç¬¬ïŒããã³ç¬¬ïŒã®è©Šè¬ãšæ··åããããšã«
ãã€ãŠæšæºæ²ç·ãäœæãããåèšæ±ºå®ãããã¢ã³
ãã€ãžãšã³ã®çžå¯Ÿéãåèšæšæºæ²ç·ãšæ¯èŒã§ãã
ããã«ãªã€ãŠããããšãç¹åŸŽãšããè£ çœ®ã ïŒïŒ åèšæšèãæŸå°æŽ»æ§æšèãé µçŽ æšèããã
ã³è¢å æšèãããªã矀ããéžæãããããšãç¹åŸŽ
ãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®è£ 眮ã ïŒïŒ åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãã¢
ã«ãã¢èå èçœè³ªãããšãªãã³ãã¬ã³èæåãã
ã絚æ¯èæ§çæ®è ºåºæ¿ãã«ã¢ã³ãããèçµåæ
åãããã³ããšããµã«ããªã°ãªã³ãããã€ã³ãã
ãªã矀ããéžæãããããšãç¹åŸŽãšããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®è£ 眮ã ïŒïŒ åèšæ«æ¢¢è¡æ¶²åæ žã¿ã€ãã®çŽ°èãåèšã¢ã³
ãã€ãžãšã³ãæ ãå¹é€ããããªã³ãçã§ããããš
ãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®è£
眮ã ïŒïŒ åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãã
ãšãªãã³ã§ãããåèšæ«æ¢¢è¡æ¶²åæ žã¿ã€ãã®çŽ°è
ãããšãªãã³ãæ ãå¹é€ããããªã³ãçã§ããã
ãšãç¹åŸŽãšããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒïŒé èšèŒã®è£
眮ã ïŒïŒ æ«æ¢¢è¡æ¶²åæ žçŽ°èäžã®ãªã³ã³ãã€ãŒã¿ã«ã¢
ã³ãã€ãžãšã³ãæ€åºããã®ã«äœ¿çšããæ¹æ³ã«ãã
ãŠã çœè¡çãµã³ãã«å ã«å«ãŸããæ«æ¢¢è¡æ¶²åæ žçŽ°è
ã®äžå®éãåèšã¢ã³ãã€ãžãšã³ã«å¯Ÿããæšèãã
ãªã³ã³ãã€ãŒã¿ã«æäœã®äžå®éãšæ··åããåèšçŽ°
èã«ä»çããªãã€ãåèšæäœãé€å»ããåèšçŽ°è
ã«ä»çããåèšæäœã®çžå¯Ÿéãåèšæšèã䜿çšã
ãŠæ±ºå®ãã第ïŒã®ãã¹ããè¡ãªãå·¥çšã åèšæ«æ¢¢è¡æ¶²åæ žçŽ°èã®ä»ã®äžå®éãæšèãã
ãããªã³ã³ãã€ãŒã¿ã«æäœã®äžå®éããã³è©°æç
ã«çµåãçŠæ¢ããéã®åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³
ãã€ãžãšã³ãšæ··åããåèšçŽ°èã«ä»çããªãã€ã
åèšæäœãé€å»ãããã®çŽ°èã«ä»çããåèšæäœ
ã®çžå¯Ÿéãåèšæšèã䜿çšããŠæ±ºå®ãã第ïŒã®ã
ã¹ããè¡ãªãå·¥çšã åèšç¬¬ïŒã第ïŒã®ãã¹ãã«ãã€ãŠåŸãããå€ã
ãåèšçŽ°èã«ãã€ãŠæ ãããŠããåèšã¢ã³ãã€ãž
ãšã³ã®çžå¯Ÿéã決å®ããçžå¯Ÿé決å®å·¥çšã åèšæ«æ¢¢è¡æ¶²åæ žçŽ°èã®æ¿ãã«æ¢ç¥ã®éã®åèš
ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãæ ãæ«æ¢¢è¡æ¶²
åæ žã¿ã€ãã®çŽ°èã䜿çšããŠåèšç¬¬ïŒã第ïŒã®ã
ã¹ãã®å·¥çšããã³çžå¯Ÿé決å®å·¥çšãè¡ãªãåç §å·¥
çšã åèšåç §å·¥çšã®çµæããæ¹æ³ã®åŠ¥åœæ§ããã³å
èšåèšæšèããæäœè©Šè¬ã®æå¹æ§ãããšãã¯ãã
ããšãã¯å·¥çšãããã³ åèšæ«æ¢¢è¡æ¶²åæ žã¿ã€ãã®çŽ°èã®æ¿ãã«åèšãª
ã³ã³ãã€ãŒã¿ã«æäœãšåå¿ããªãããšãç¥ãããŠ
ããèçœç©è³ªãæ ã现èã䜿çšããŠåèšç¬¬ïŒã®ã
ã¹ãã®å·¥çšã第ïŒã®ãã¹ãã®å·¥çšãçžå¯Ÿé決å®å·¥
çšãåç §å·¥çšãããã³ããšãã¯å·¥çšãç¹°ãè¿ãå·¥
çšã ãããªãããšãç¹åŸŽãšããæ¹æ³ã ïŒïŒ æ«æ¢¢è¡æ¶²åæ žçŽ°èäžã®ãªã³ã³ãã€ãŒã¿ã«ã¢
ã³ãã€ãžãšã³ãæ€åºããã®ã«äœ¿çšããæ¹æ³ã«ãã
ãŠã çœè¡çãµã³ãã«å ã«å«ãŸããæ«æ¢¢è¡æ¶²åæ žçŽ°è
ã®äžå®éãåèšã¢ã³ãã€ãžãšã³ã«å¯Ÿããæšèãã
ãªã³ã³ãã€ãŒã¿ã«æäœã®äžå®éãšæ··åããåèšçŽ°
èã«ä»çããªãã€ãåèšæäœãé€å»ããåèšçŽ°è
ã«ä»çããåèšæäœã®çžå¯Ÿéãåèšæšèã䜿çšã
ãŠæ±ºå®ãã第ïŒã®ãã¹ããè¡ãªãå·¥çšã åèšæ«æ¢¢è¡æ¶²åæ žçŽ°èã®ä»ã®äžå®éãæšèãã
ãããªã³ã³ãã€ãŒã¿ã«æäœã®äžå®éããã³è©°æç
ã«çµåãçŠæ¢ããéã®åèšãªã³ã³ãã€ãŒã¿ã«ã¢ã³
ãã€ãžãšã³ãšæ··åããåèšçŽ°èã«ä»çããªãã€ã
åèšæäœãé€å»ãããã®çŽ°èã«ä»çããåèšæäœ
ã®çžå¯Ÿéãåèšæšèã䜿çšããŠæ±ºå®ãã第ïŒã®ã
ã¹ããè¡ãªãå·¥çšã åèšç¬¬ïŒã第ïŒã®ãã¹ãã«ãã€ãŠåŸãããå€ã
ãåèšçŽ°èã«ãã€ãŠæ ãããŠããåèšã¢ã³ãã€ãž
ãšã³ã®çžå¯Ÿéã決å®ããçžå¯Ÿé決å®å·¥çšã åèšæ«æ¢¢è¡æ¶²åæ žçŽ°èã®æ¿ãã«æ¢ç¥ã®éã®åèš
ãªã³ã³ãã€ãŒã¿ã«ã¢ã³ãã€ãžãšã³ãæ ãæ«æ¢¢è¡æ¶²
åæ žã¿ã€ãã®çŽ°èã䜿çšããŠåèšç¬¬ïŒã第ïŒã®ã
ã¹ãã®å·¥çšããã³çžå¯Ÿé決å®å·¥çšãè¡ãªãåç §å·¥
çšã åèšåç §å·¥çšã®çµæããæ¹æ³ã®åŠ¥åœæ§ããã³å
èšåèšæšèããæäœè©Šè¬ã®æå¹æ§ãããšãã¯ãã
ããšãã¯å·¥çšã åèšã¢ã³ãã€ãžãšã³ãæå®ã®éã®åºå®ãããæ
äœããã³æå®ã®éã®æšèããæäœãšãéã次第ã«
å¢ãããªããæ··åããæšæºæ²ç·ãäœæããæšæºæ²
ç·äœæå·¥çšã åèšæšèã䜿çšããŠåã¢ã³ãã€ãžãšã³æ¿åºŠã«ã
ããç¹ç°ççµåã決å®ããå·¥çšãããã³ åèšçžå¯Ÿé決å®å·¥çšã«ãã€ãŠåŸãããå€ãåèš
æšæºæ²ç·ãšæ¯èŒããŠãã®å€ã«å¯Ÿå¿ããã¢ã³ãã€ãž
ãšã³ã®éã決å®ããå·¥çšã åèšæ«æ¢¢è¡æ¶²åæ žã¿ã€ãã®çŽ°èã®æ¿ãã«åèšãª
ã³ã³ãã€ãŒã¿ã«æäœãšåå¿ããªãããšãç¥ãããŠ
ããèçœç©è³ªãæ ã现èã䜿çšããŠåèšç¬¬ïŒã®ã
ã¹ãã®å·¥çšã第ïŒã®ãã¹ãã®å·¥çšãçžå¯Ÿé決å®å·¥
çšãåç §å·¥çšãããšãã¯å·¥çšãæšæºæ²ç·äœæå·¥çš
ããã³åèšç¹ç°ççµåã決å®ããå·¥çšãç¹°ãè¿ã
å·¥çšã ãããªãããšãç¹åŸŽãšããæ¹æ³ã
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14792880A | 1980-05-08 | 1980-05-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS576364A JPS576364A (en) | 1982-01-13 |
| JPH0121909B2 true JPH0121909B2 (ja) | 1989-04-24 |
Family
ID=22523493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6924681A Granted JPS576364A (en) | 1980-05-08 | 1981-05-08 | Immunologic inspection of oncofetal antigent and diagnostic method and kit utilizing thereof |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0040058B1 (ja) |
| JP (1) | JPS576364A (ja) |
| AT (1) | ATE15108T1 (ja) |
| CA (1) | CA1166957A (ja) |
| DE (1) | DE3171892D1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4598051A (en) * | 1980-03-12 | 1986-07-01 | The Regents Of The University Of California | Liposome conjugates and diagnostic methods therewith |
| US4806466A (en) * | 1981-10-29 | 1989-02-21 | The Regents Of The University Of California | Cell agglutination reagent comprising conjugates of antibody covalently bound to liposomes |
| JPS5915858A (ja) * | 1982-07-16 | 1984-01-26 | Otsuka Pharmaceut Co Ltd | è «çé¢é£æåç¹ç°çå ç«è€åäœã®æž¬å®æ³ |
| ES2164071T3 (es) * | 1992-03-27 | 2002-02-16 | Abbott Lab | Control de verificacion de dosificado para metodos de analisis. |
| CA2137784A1 (en) * | 1993-04-22 | 1994-10-27 | Kathryn Herring | Tumor marker control |
| US5747268A (en) * | 1993-04-22 | 1998-05-05 | Dade International Inc. | Tumor marker control |
| EP1225233A3 (en) * | 2001-01-23 | 2003-01-08 | Amsterdam Support Diagnostics B.V. | Means and methods for treatment evaluation |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4152410A (en) * | 1975-09-03 | 1979-05-01 | Eisai Co., Ltd. | Diagnosis reagent for neoplasm and method for diagnosis of neoplasm |
| US3988115A (en) * | 1975-09-18 | 1976-10-26 | Modabber Farrokh Z | Diagnostic method for determining pathological condition by antigen-combining capacity of lymphocytes |
| US4116776A (en) * | 1976-04-19 | 1978-09-26 | International Radioimmune Systems, Inc. | Diagnostic blood test and kit for detecting human chorionic gonadotropin |
| US4144031A (en) * | 1976-04-19 | 1979-03-13 | International Radioimmune Systems, Inc. | Cell test for detecting human chorionic gonadotropin |
| US4140753A (en) * | 1976-04-30 | 1979-02-20 | Scripps Clinic & Research Foundation | Diagnostic method and reagent |
-
1981
- 1981-05-04 CA CA000376821A patent/CA1166957A/en not_active Expired
- 1981-05-08 DE DE8181302036T patent/DE3171892D1/de not_active Expired
- 1981-05-08 JP JP6924681A patent/JPS576364A/ja active Granted
- 1981-05-08 AT AT81302036T patent/ATE15108T1/de not_active IP Right Cessation
- 1981-05-08 EP EP81302036A patent/EP0040058B1/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| EP0040058A1 (en) | 1981-11-18 |
| DE3171892D1 (en) | 1985-09-26 |
| JPS576364A (en) | 1982-01-13 |
| CA1166957A (en) | 1984-05-08 |
| ATE15108T1 (de) | 1985-09-15 |
| EP0040058B1 (en) | 1985-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4584268A (en) | Method and compositions for carcinoma diagnosis | |
| Ruoslahti et al. | Studies of carcinoâfetal proteins. III. Development of a radioimmunoassay for αâfetoprotein. Demonstration of αâfetoprotein in serum of healthy human adults | |
| EP1952156B1 (en) | Diagnostic method for preeclampsia | |
| US6251616B1 (en) | Methods and assay kits for detecting altered mononuclear cell phenotype related to a pro-tumor immune response | |
| JP2002532686A (ja) | çæ€åºæ³ããã³è©Šè¬ | |
| US20090291920A1 (en) | Detection of steroid receptors on circulating carcinoma cells and treatment | |
| JPS58758A (ja) | ããèå æ§æåã®å®éæ¹æ³ | |
| US4116776A (en) | Diagnostic blood test and kit for detecting human chorionic gonadotropin | |
| JPH09506173A (ja) | åºç£åã®è䟿ã®æ€åº | |
| JPH03229153A (ja) | ãªã¥ãŠããç ã®èšºæã«æçšãªç¹ç°çæäœãŸãã¯æåã®ååšãæ€åºããæ¹æ³ããã³ããã«çšãããããã¹ãããã | |
| JPH0121909B2 (ja) | ||
| KR101083420B1 (ko) | ì ë°©ì ì§ëšì© ë¹ì¿šëŠ° ìê°í첎 ë° ìŽë¥Œ ìŽì©í ì§ëší€íž | |
| EP0080259B1 (en) | Method and compositions for carcinoma diagnosis | |
| Anderson et al. | Preclinical warning of recrudescent mammary cancers by pregnancyâassociated alphaâmacroglobulin | |
| JP2022104553A (ja) | ã«åºã¥ããŠïŒµïŒïŒ¯ïŒ€ã修食ããå°¿äžã®ïŒ®ïœ ïœïŒïŒ§ïœãèå¥ããå°¿è·¯äžç®çã®æ€æ»çšããããããã³ãã®è£œé æ¹æ³ | |
| Mortensen et al. | Prognostic significance of serum CRP levels and lymphoid cell infiltrates in human breast cancer | |
| JPH0616048B2 (ja) | ãã£ãããã¯ãã³ã®å ç«åŠçæž¬å® | |
| CA2486119A1 (en) | Method of isolating an endothelial cell and method of donor specific crossmatching | |
| Tsou et al. | Evaluation of 5â²ânucleotide phosphodiesterase isozymeâV as a predictor for liver metastasis in breast cancer patients | |
| CA2246372A1 (en) | Foetal cell analysis | |
| CA1196861A (en) | Immunoassay for oncofetal antigen carried by lymphocytes | |
| US6376201B2 (en) | Use of ligands specific to major histocompatibility complex-class I antigens for diagnosing endometriosis | |
| JPH0772149A (ja) | èçåã¯è硬å€ã®èšºæè¬åã³èšºææ³ | |
| JP3308027B2 (ja) | äžåã¯ããããå€ã被åæç©è³ªã®å ç«åŠç枬å®ã®ããã®èšºææ¹æ³ | |
| JP3183717B2 (ja) | è «ç现èã®ååšã®æç¡ã®å€å®æ¹æ³ |